<?xml version="1.0" encoding="UTF-8"?>
<HL7Messages MessageFormat="ORUR01" MessageCount="18" Version="2.3"><Message MsgID="1"><![CDATA[MSH|^~\&|PATHL7|BCB|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551204|P|2.3|||ER|AL
PID||9039676767|||EXCELLERIS^BBPATIENT||19490614|M|||||604 775-9696
ORC|RE||13-9009096-URC-0|||||||||90909^MDCARE^BOB
OBR|1||13-9009096-URC-0|URC^Urine Culture||20130601092800|20130601092800|||||||20130601092800||90909^MDCARE^BOB||131133796||||20130604112000||MICRO3|F|||90909^MDCARE^BOB
NTE|||\.br\\.br\Reviewed by Microbiologist.(604-507-5000).
OBX|1|TX|33882-2^Collection Date||13/06/01|YY/MM/DD|||||F|||20130601092900
OBX|2|FT|19803-6^Site||Urine, Midstream||||||F|||20130601092900
OBX|3|FT|6463-4^Organism|2|<10 mega CFU/Litre Pseudomonas aeruginosa|||A|||F|||20130604084200
OBX|4|FT|133-9^Ceftazidime|2|S||||||F|||20130604084200
OBX|5|FT|408-5^Piperacillin|2|S||||||F|||20130604084200
OBX|6|FT|6652-2^Meropenem|2|R||||||F|||20130604084200
OBX|7|FT|185-9^Ciprofloxacin|2|R||||||F|||20130604084200
OBX|8|FT|267-5^Gentamicin|2|S||||||F|||20130604084200
OBX|9|FT|508-2^Tobramycin|2|S||||||F|||20130604084200
OBX|10|FT|12-5^Amikacin|2|S||||||F|||20130604084200
]]></Message><Message MsgID="2"><![CDATA[MSH|^~\&|PATHL7|CW|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551205|P|2.3|||ER|AL
PID||1008203001|1008203001||EXCELLERIS^OPATIENT||20051112|M|||||604-658-2003
ORC|RE||QA9924-20007007-HP-1|||||||||90909^MDCARE^BOB
OBR|1||QA9924-20007007-HP-1|HP^Hematology Panel||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130722124114||HAEM1|F|||90909^MDCARE^BOB
OBX|1|NM|6690-2^WBC||6.0|X10 9/L|3.9-10.2||||F|||20130722124108
OBX|2|NM|789-8^RBC||4.58|X10 12/L|4.05-5.15||||F|||20130722124108
OBX|3|NM|718-7^Hemoglobin||128|g/L|118-146||||F|||20130722124108
OBX|4|NM|20570-8^Hematocrit (whole blood)||0.370||0.350-0.430||||F|||20130722124108
OBX|5|NM|787-2^MCV||80.8|fl|77.0-92.0||||F|||20130722124108
OBX|6|NM|785-6^MCH||27.9|pg|25.8-31.7||||F|||20130722124108
OBX|7|NM|788-0^RDW||0.133||0.116-0.148||||F|||20130722124108
OBX|8|NM|26515-7^Platelet Count||261|X10 9/L|180-440||||F|||20130722124108
OBX|9|NM|28542-9^MPV||9.3|fl|8.6-11.1||||F|||20130722124108
OBX|10|NM|26499-4^Neutrophils||1.84|X10 9/L|1.70-5.00||||F|||20130722124114
OBX|11|NM|26474-7^Lymphocytes||3.23|X10 9/L|1.90-4.30||||F|||20130722124114
OBX|12|NM|26484-6^Monocytes||0.37|X10 9/L|0.10-0.70||||F|||20130722124114
OBX|13|NM|26449-9^Eosinophils||0.45|X10 9/L|0.00-0.70||||F|||20130722124114
OBX|14|NM|26444-0^Basophils||0.06|X10 9/L|0.00-0.10||||F|||20130722124114
ORC|RE||QA9924-20007007-PT-1|||||||||90909^MDCARE^BOB
OBR|2||QA9924-20007007-PT-1|PT^INR||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130722124002||HAEM3|F|||90909^MDCARE^BOB
OBX|1|NM|6301-6^INR||1.10|ratio|0.87-1.11||||F|||20130722124002
OBX|2|NM|5902-2^Prothrombin Time||11.9|sec|9.6-12.0||||F|||20130722124002
ORC|RE||QA9924-20007007-BGSV-1|||||||||90909^MDCARE^BOB
OBR|3||QA9924-20007007-BGSV-1|BGSV^Blood Gases Venous||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130722121835||CHEM3.5|F|||90909^MDCARE^BOB
OBX|1|NM|2746-6^Venous pH||7.35||7.35-7.45||||F|||20130722121835
OBX|2|NM|2021-4^Venous pCO2||45|mmHG|||||F|||20130722121835
OBX|3|NM|2705-2^Venous pO2||30|mmHG|||||F|||20130722121835
OBX|4|NM|14627-4^Venous HCO3||23|mmol/L|||||F|||20130722121835
OBX|5|NM|1924-0^Venous Base Deficit||1.0|mmol/L|||||F|||20130722121835
ORC|RE||QA9924-20007007-ANA-1|||||||||90909^MDCARE^BOB
OBR|4||QA9924-20007007-ANA-1|ANA^Nuclear Ab||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130729135939||CHEM18|F|||90909^MDCARE^BOB
OBX|1|FT|8061-4^Nuclear Ab||Negative||||||F|||20130729135939
ORC|RE||QA9924-20007007-ACABS-1|||||||||90909^MDCARE^BOB
OBR|5||QA9924-20007007-ACABS-1|ACABS^Blood Spot Acylcarnitine||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130725143900||GENETIC1|F|||90909^MDCARE^BOB
OBX|1|FT|XXX-0035^Date of Assay||23/JUL/2013||||||F|||20130725143900
OBX|2|NM|38481-8^Bld Spot Carnitine Free (C0)||31.3|umol/L|14.44-55.7||||F|||20130725143900
OBX|3|NM|50157-7^Bld Spot Acetylcarnitine (C2)||15.4|umol/L|7.75-27.8||||F|||20130725143900
OBX|4|NM|53160-8^Bld Spot Propionylcarnitine (C3)||0.89|umol/L|0.56-3.22||||F|||20130725143900
OBX|5|NM|53065-9^Bld Spot Butyrylcarnitine (C4)||0.12|umol/L|0.1-0.47||||F|||20130725143900
OBX|6|FT|53170-7^Bld Spot Tiglylcarnitine (C5:1)||None Detected|umol/L|0.01-0.05||||F|||20130725143900
OBX|7|NM|42920-9^Bld Spot Isovalerylcarnitine (C5)||0.12|umol/L|0.07-0.32||||F|||20130725143900
OBX|8|NM|50102-3^Bld Spot 3-Hydroxybutyrylcarnitine (C4-OH)||0.07|umol/L|0.03-0.21||||F|||20130725143900
OBX|9|NM|45211-0^Bld Spot Hexanoylcarnitine (C6)||0.05|umol/L|0.03-0.15||||F|||20130725143900
OBX|10|NM|50106-4^Bld Spot 3-Hydroxyisovalerylcarnitine (C5-OH)||0.15|umol/L|0.07-0.56||||F|||20130725143900
OBX|11|NM|53174-9^Bld Spot Octenoylcarnitine (C8:1)||0.10|umol/L|0.07-0.5||||F|||20130725143900
OBX|12|NM|53175-6^Bld Spot Octanoylcarnitine (C8)||0.09|umol/L|0.02-0.18||||F|||20130725143900
OBX|13|NM|54462-7^Bld Spot Malonylcarnitine (C3-DC)||0.06|umol/L|0-0.11||||F|||20130725143900
OBX|14|NM|45198-9^Bld Spot Decenoylcarnitine (C10:1)||0.06|umol/L|0.02-0.22||||F|||20130725143900
OBX|15|NM|45197-1^Bld Spot Decanoylcarnitine (C10)||0.11|umol/L|0.02-0.23||||F|||20130725143900
OBX|16|NM|45222-7^Bld Spot Methylmalonylcarnitine (C4-DC)||0.47|umol/L|0.2-1.48||||F|||20130725143900
OBX|17|NM|45207-8^Bld Spot Glutarylcarnitine (C5-DC)||0.03|umol/L|0-0.07||||F|||20130725143900
OBX|18|NM|45200-3^Bld Spot Dodecenoylcarnitine (C12:1)||0.03|umol/L|0.01-0.11||||F|||20130725143900
OBX|19|NM|45199-7^Bld Spot Dodecanoylcarnitine (C12)||0.05|umol/L|0.02-0.13||||F|||20130725143900
OBX|20|NM|53187-1^Bld Spot Methylglutarylcarnitine (C6-DC)||0.01|umol/L|0.01-0.04||||F|||20130725143900
OBX|21|NM|53188-9^Bld Spot 3-Hydroxydodecenoylcarnitine (C12:1-OH)||0.01|umol/L|0-0.03||||F|||20130725143900
OBX|22|NM|53189-7^Bld Spot 3-Hydroxydodecanoylcarnitine (C12-OH)||0.01|umol/L|0.01-0.04||||F|||20130725143900
OBX|23|NM|53190-5^Bld Spot Tetradecadienoylcarnitine (C14:2)||0.03|umol/L|0.01-0.06||||F|||20130725143900
OBX|24|NM|53191-3^Bld Spot Tetradecenoylcarnitine (C14:1)||0.05|umol/L|0.02-0.17||||F|||20130725143900
OBX|25|NM|53192-1^Bld Spot Tetradecanoylcarnitine (C14)||0.07|umol/L|0.04-0.25||||F|||20130725143900
OBX|26|NM|53210-1^Bld Spot Suberylcarnitine (C8-DC)||0.01|umol/L|0.01-0.03||||F|||20130725143900
OBX|27|NM|53197-0^Bld Spot 3-Hydroxytetradecenoylcarnitine (C14:1-OH)||0.02|umol/L|0.01-0.06||||F|||20130725143900
OBX|28|NM|50281-5^Bld Spot 3-Hydroxytetradecanoylcarnitine (C14-OH)||0.01|umol/L|0.01-0.04||||F|||20130725143900
OBX|29|NM|53199-6^Bld Spot Palmitoylcarnitine (C16)||0.72|umol/L|0.33-1.64||||F|||20130725143900
OBX|30|NM|50121-3^Bld Spot 3-Hydroxypalmitoleylcarnitine (C16:1-OH)||0.02|umol/L|0.01-0.08||||F|||20130725143900
OBX|31|FT|50125-4^Bld Spot 3-Hydroxypalmitoylcarnitine (C16-OH)||None Detected|umol/L|0-0.04||||F|||20130725143900
OBX|32|NM|45217-7^Bld Spot Linoleoylcarnitine (C18:2)||0.21|umol/L|0.11-0.68||||F|||20130725143900
OBX|33|NM|53202-8^Bld Spot Oleoylcarnitine (C18:1)||0.80|umol/L|0.38-2.12||||F|||20130725143900
OBX|34|NM|53241-6^Bld Spot Stearoylcarnitine (C18)||0.44|umol/L|0.14-1.19||||F|||20130725143900
OBX|35|NM|50109-8^Bld Spot 3-Hydroxylinoleoylcarnitine (C18:2-OH)||0.01|umol/L|0-0.02||||F|||20130725143900
OBX|36|NM|50113-0^Bld Spot 3-Hydroxyoleoylcarnitine (C18:1-OH)||0.01|umol/L|0-0.03||||F|||20130725143900
OBX|37|FT|53218-4^Bld Spot Dicarboxypalmitoylcarnitine (C16-DC)||None Detected|umol/L|0-0.01||||F|||20130725143900
OBX|38|NM|53219-2^Bld Spot Dicarboxyoleylcarnitine (C18:1-DC)||0.01|umol/L|0-0.03||||F|||20130725143900
OBX|39|NM|38474-3^Bld Spot Acylcarnitine||20.2|umol/L|6.97-39.76||||F|||20130725143900
OBX|40|NM|38480-0^Bld Spot Carnitine||51.5|umol/L|19.98-92.41||||F|||20130725143900
OBX|41|NM|59249-3^Bld Spot Acylcarnitine/Acylcarnitine+Carnitine Free (C0)||0.39||0.35-0.43||||F|||20130725143900
OBX|42|NM|53162-4^Bld Spot Propionylcarnitine (C3)/Carnitine Free (C0)||0.03||0.02-0.15||||F|||20130725143900
OBX|43|NM|53163-2^Bld Spot Propionylcarnitine (C3)/Acetylcarnitine (C2)||0.06||0.03-0.22||||F|||20130725143900
OBX|44|NM|53177-2^Bld Spot Octanoylcarnitine (C8)/Decanoylcarnitine (C10)||0.81||0.61-1.78||||F|||20130725143900
OBX|45|NM|53176-4^Bld Spot Octanoylcarnitine (C8)/Acetylcarnitine (C2)||0.006||0-0.009||||F|||20130725143900
OBX|46|NM|XBC2748-5^Bld Spot Glutarylcarnitine (C5-DC)/Carnitine||0.001||0-0.002||||F|||20130725143900
OBX|47|NM|XBC2752-0^Bld Spot Glutarylcarnitine (C5-DC)/Palmitoylcarnitine (C16)||0.044||0-0.08||||F|||20130725143900
OBX|48|NM|XBC2751-3^Bld Spot Glutarylcarnitine (C5DC)/Octanoylcarnitine+Decanoylcarnitine (C8+C10)||0.155||0-0.4||||F|||20130725143900
OBX|49|NM|53235-8^Bld Spot Carnitine Free (C0)/Palmityolcarnitine (C16)+Stearoylcarnitine (C18)||27.13||10.72-49.9||||F|||20130725143900
OBX|50|NM|59243-6^Bld Spot Palmitoylcarnitine (C3)+Oleoylcarnitine (C18:1)/Acetylcarnitine (C2)||0.10||0.05-0.18||||F|||20130725143900
OBX|51|NM|53201-0^Bld Spot 3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)||0.01||0.007-0.039||||F|||20130725143900
OBX|52|NM|XBC2750-4^Bld Spot Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14)||0.67||0.22-1.5||||F|||20130725143900
OBX|53|NM|53193-9^Bld Spot Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2)||0.003||0.001-0.007||||F|||20130725143900
OBX|54|FT|XXX-0026^Pathologist Comment||Unremarkable acylcarnitine profile in bloodspot.\.br\No evidence for a fatty acid oxidation disorder.\.br\H.V.MD,FRCP(C),FCCMG\.br\Biochemical Genetics Lab, (604)8752307||||||F|||20130725143900
ORC|RE||QA9924-20007007-AAP-1|||||||||90909^MDCARE^BOB
OBR|6||QA9924-20007007-AAP-1|AAP^Plasma Amino Acids||20130722111400|20130722114300|||||||20130722114900||90909^MDCARE^BOB||||||20130807100010||GENETIC1|F|||90909^MDCARE^BOB
OBX|1|FT|XXX-0035^Date of Assay||02AUG2013||||||F|||20130807100010
OBX|2|NM|22664-7^Urea||2775|umol/L|||||F|||20130807100010
OBX|3|NM|20657-3^Taurine||41|umol/L|<241||||F|||20130807100010
OBX|4|NM|20639-1^Aspartate||4|umol/L|<15||||F|||20130807100010
OBX|5|NM|20647-4^Hydroxyproline||5|umol/L|<51||||F|||20130807100010
OBX|6|NM|20658-1^Threonine||109|umol/L|74-202||||F|||20130807100010
OBX|7|NM|20656-5^Serine||115|umol/L|71-181||||F|||20130807100010
OBX|8|NM|20642-5^Glutamate||18|umol/L|7-65||||F|||20130807100010
OBX|9|NM|20643-3^Glutamine||549|umol/L|360-740||||F|||20130807100010
OBX|10|NM|20655-7^Proline||136|umol/L|58-324||||F|||20130807100010
OBX|11|NM|20644-1^Glycine||210|umol/L|158-302||||F|||20130807100010
OBX|12|NM|20636-7^Alanine||263|umol/L|193-545||||F|||20130807100010
OBX|13|NM|20640-9^Citrulline||17|umol/L|19-52|L|||F|||20130807100010
OBX|14|NM|20634-2^Alpha Aminobutyrate||13|umol/L|8-36||||F|||20130807100010
OBX|15|NM|20661-5^Valine||197|umol/L|156-288||||F|||20130807100010
OBX|16|NM|22672-0^Cystine||39|umol/L|36-58||||F|||20130807100010
OBX|17|NM|20651-6^Methionine||19|umol/L|16-37||||F|||20130807100010
OBX|18|NM|20648-2^Isoleucine||49|umol/L|38-95||||F|||20130807100010
OBX|19|NM|20649-0^Leucine||70|umol/L|79-174|L|||F|||20130807100010
OBX|20|NM|20660-7^Tyrosine||50|umol/L|43-88||||F|||20130807100010
OBX|21|NM|14875-9^Phenylalanine||42|umol/L|39-76||||F|||20130807100010
OBX|22|NM|20652-4^Ornithine||37|umol/L|19-81||||F|||20130807100010
OBX|23|NM|20650-8^Lysine||136|umol/L|108-233||||F|||20130807100010
OBX|24|NM|20645-8^Histidine||91|umol/L|64-106||||F|||20130807100010
OBX|25|NM|20637-5^Arginine||69|umol/L|44-130||||F|||20130807100010
OBX|26|FT|XXX-0104^Chromatogram Number||02G79||||||F|||20130807100010
OBX|27|FT|XXX-0026^Pathologist Comment||Unremarkable plasma amino acid profile.\.br\G.S., PhD, FCCMG\.br\Biochemical Geneticist, (604)8752307||||||F|||20130807100010
]]></Message><Message MsgID="3"><![CDATA[MSH|^~\&|PATHL7|CDC|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551206|P|2.3|||ER|AL
PID||1009000111|D1009000111||EXCELLERIS^DPATIENT||19801018|F|||||604-658-2211
ORC|RE||QA999722-99969066-GCM-1|||||||||90909^MDCARE^BOB
OBR|1||QA999722-99969066-GCM-1|GCM^General Information||20130802150000|20130801123000|||||||20130802150000||90909^MDCARE^BOB||||||||GENERAL|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
NTE|||Submitter's ref number: rch: 13:rt0003120m
ORC|RE||QA999722-99969066-AFBC-1|||||||||90909^MDCARE^BOB
OBR|2||QA999722-99969066-AFBC-1|AFBC^AFB Culture||20130802150000|20130801123000|||||||20130802150000||90909^MDCARE^BOB||||||20130917161128||MICRO3|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|FT|XXX-0002^Specimen Description||Sputum||||||F|||20130802150052
OBX|2|FT|XXX-0007^Special Requests||None||||||F|||20130802150052
OBX|3|FT|XXX-0006^Report Status||Final 17/Sep/2013||||||F|||20130917161128
OBX|4|FT|11545-1^Acid Fast Stain||No acid fast bacilli found.\.br\Very little material for examination.||||||F|||20130806124659
OBX|5|FT|6463-4^Culture|1|No growth of M.tuberculosis or other Mycobacteria after 6 weeks incubation.||||||F|||20130917161128
]]></Message><Message MsgID="4"><![CDATA[MSH|^~\&|PATHL7|VML|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551207|P|2.3|||ER|AL
PID||9012050878|||EXCELLERIS^CCPATIENT||19391016|M|||||(250)764-6666
ORC|RE||M99970-MCOM-0|||||||||90909^MDCARE^BOB
OBR|1||M99970-MCOM-0|MCOM^Microbiology Comment||20130816151908|20130816151908|||||||20130816151908||90909^MDCARE^BOB||||||20130820113052||GENERAL|F|||90909^MDCARE^BOB
NTE|||Clinical Information:   Nasal
ORC|RE||M99970-MRSA-0|||||||||90909^MDCARE^BOB
OBR|2||M99970-MRSA-0|MRSA^Screen for MRSA|R|20130816151908|20130816151908|||||||20130816151908||90909^MDCARE^BOB||||||20130820113052||MICRO3|F||^^^^^R|90909^MDCARE^BOB
OBX|1|TX|19803-6^Site||Source: MRSA Screen (nasal/nares, axilla, groin)||||||F|||20130816151908
OBX|2|TX|X30011^Organism|1|Staphylococcus aureus (MRSA)   Scant Growth||||||F|||20130816151908
NTE|||MRSA isolated. Patient should be notified in the event of admission to a healthcare facility. Copy sent to Infection Control.
OBX|3|TX|X10342^Oxacillin-Cloxacillin|1|R||||||R|||20130820113052
OBX|4|TX|193-3^Clindamycin|1|S||||||R|||20130820113052
OBX|5|TX|516-5^Trimethoprim-Sulfa|1|S||||||R|||20130820113052
OBX|6|TX|20396-8^Levofloxacin|1|R||||||R|||20130820113052
OBX|7|TX|31037-5^Moxifloxacin|1|R||||||R|||20130820113052
OBX|8|TX|496-0^Tetracycline|1|S||||||R|||20130820113052
OBX|9|TX|524-9^Vancomycin|1|S||||||R|||20130820113052
]]></Message><Message MsgID="5"><![CDATA[MSH|^~\&|PATHL7|PHC|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551208|P|2.3|||ER|AL
PID||9111494949|7963143||EXCELLERIS^HHPATIENT||19550824|M|||||604-687-6123
ORC|RE||QA999031-20000020-HP-1|||||||||90909^MDCARE^BOB
OBR|1||QA999031-20000020-HP-1|HP^Hematology Panel||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130903225945||HAEM1|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|12227-5^WBC||7.1|giga/L|4.0-11.0||||F|||20130903225945
OBX|2|NM|789-8^RBC||4.14|tera/L|4.20-5.80|L|||F|||20130903225945
OBX|3|NM|718-7^Hemoglobin||128|g/L|135-170|L|||F|||20130903225945
OBX|4|NM|4544-3^Hematocrit||0.37||0.40-0.50|L|||F|||20130903225945
OBX|5|NM|787-2^MCV||88|fL|82-98||||F|||20130903225945
OBX|6|NM|788-0^RDW||13.6|%|11.0-15.0||||F|||20130903225945
OBX|7|NM|777-3^Platelet Count||178|giga/L|150-400||||F|||20130903225945
OBX|8|NM|32623-1^MPV||10.3|fL|9.5-12.5||||F|||20130903225945
ORC|RE||QA999031-20000020-IBR-1|||||||||90909^MDCARE^BOB
OBR|2||QA999031-20000020-IBR-1|IBR^Iron / TIBC||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM1|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|14798-3^Iron||18|umol/L|7-32||||F|||20130904005333
ORC|RE||QA999031-20000020-FRT-1|||||||||90909^MDCARE^BOB
OBR|3||QA999031-20000020-FRT-1|FRT^Ferritin||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904094713||CHEM1|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|FT|2276-4^Ferritin||211\.br\Iron deficiency unlikely. If serum ferritin is persistently >600 ug/L consider test for iron overload. See www.bcguidelines.ca|ug/L|15-300||||F|||20130904094713
ORC|RE||QA999031-20000020-TRFT-1|||||||||90909^MDCARE^BOB
OBR|4||QA999031-20000020-TRFT-1|TRFT^Transferrin||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM1|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|3034-6^Transferrin||1.57|g/L|1.75-3.60|L|||F|||20130904005333
OBX|2|NM|6796-7^Transferrin Saturation||0.46||0.12-0.36|H|||F|||20130904005333
ORC|RE||QA999031-20000020-LYTE-1|||||||||90909^MDCARE^BOB
OBR|5||QA999031-20000020-LYTE-1|LYTE^Electrolytes||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|2951-2^Sodium||131|mmol/L|135-148|L|||F|||20130903231647
OBX|2|NM|2823-3^Potassium||4.1|mmol/L|3.6-4.7||||F|||20130903231647
OBX|3|NM|1963-8^Bicarbonate||19|mmol/L|22-31|L|||F|||20130904005333
ORC|RE||QA999031-20000020-BUN-1|||||||||90909^MDCARE^BOB
OBR|6||QA999031-20000020-BUN-1|BUN^Urea||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|14937-7^Urea||14.5|mmol/L|2.5-8.0|H|||F|||20130904005333
ORC|RE||QA999031-20000020-CRE-1|||||||||90909^MDCARE^BOB
OBR|7||QA999031-20000020-CRE-1|CRE^Creatinine/eGFR||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|14682-9^Creatinine||646|umol/L|60-100|H|||F|||20130904005333
ORC|RE||QA999031-20000020-CA-1|||||||||90909^MDCARE^BOB
OBR|8||QA999031-20000020-CA-1|CA^Calcium||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|2000-8^Calcium||2.39|mmol/L|2.18-2.58||||F|||20130904005333
ORC|RE||QA999031-20000020-PO4-1|||||||||90909^MDCARE^BOB
OBR|9||QA999031-20000020-PO4-1|PO4^Phosphorus||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|14879-1^Phosphorus||1.67|mmol/L|0.80-1.60|H|||F|||20130904005333
ORC|RE||QA999031-20000020-ALB-1|||||||||90909^MDCARE^BOB
OBR|10||QA999031-20000020-ALB-1|ALB^Albumin||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|1751-7^Albumin||42|g/L|35-48||||F|||20130904005333
ORC|RE||QA999031-20000020-ALK-1|||||||||90909^MDCARE^BOB
OBR|11||QA999031-20000020-ALK-1|ALK^Alkaline Phosphatase||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904005333||CHEM4|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|6768-6^Alkaline Phosphatase||150|U/L|30-105|H|||F|||20130904005333
ORC|RE||QA999031-20000020-CRP-1|||||||||90909^MDCARE^BOB
OBR|12||QA999031-20000020-CRP-1|CRP^C Reactive Protein||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904023410||CHEM17|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|30522-7^C Reactive Protein (High Sensitivity)||7.1|mg/L|<3.1|H|||F|||20130904023410
OBX|2|FT|X10083^Test Comment||If ESR was also requested, only CRP will be processed.||||||F|||20130901141058
ORC|RE||QA999031-20000020-PTH-1|||||||||90909^MDCARE^BOB
OBR|13||QA999031-20000020-PTH-1|PTH^Parathyroid Hormone||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130904145615||CHEM28|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|14866-8^Parathyroid Hormone Intact||37.1|pmol/L|1.3-6.8|H|||F|||20130904145615
ORC|RE||QA999031-20000020-B2M-1|||||||||90909^MDCARE^BOB
OBR|14||QA999031-20000020-B2M-1|B2M^Beta 2 Microglobulin||20130901141000|20130903224500|||||||20130903225700||90909^MDCARE^BOB||||||20130905140645||TUMOUR-LAB|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|NM|XBC3678-2^Beta 2 Microglobulin||15|mg/L|<2|H|||F|||20130905140645
]]></Message><Message MsgID="6"><![CDATA[MSH|^~\&|PATHL7|LIFELABS|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551209|P|2.3|||ER|AL
PID||9061222333||7029|EXCELLERIS^AAPATIENT||19521120|F|||||(604)944-4444
ORC|RE||13-900900065-ELBW-1|||||||||90909^MDCARE^BOB
OBR|1||13-900900065-ELBW-1|ELBW^Elbow Culture||20130905194300|20130904|||||||20130905194300||90909^MDCARE^BOB||||||20130909135015||MICRO3|F|||90909^MDCARE^BOB~C1711^NAOMI CLINIC
OBX|1|FT|X805^Comment||RIGHT\.br\Specimen received one day after \.br\collection.\.br\||||||F|||20130909135015
OBX|2|ST|X10114^Report Status||Final||||||F|||20130909135015
OBX|3|FT|664-3^Gram Stain||RARE EPITHELIAL CELLS\.br\||||||F|||20130909135015
OBX|4|FT|X800^Gram Stain||FEW NEUTROPHILS\.br\||||||F|||20130909135015
OBX|5|FT|X801^Gram Stain||MODERATE GRAM POSITIVE COCCI\.br\||||||F|||20130909135015
OBX|6|FT|X802^Gram Stain||FEW GRAM NEGATIVE BACILLI\.br\||||||F|||20130909135015
OBX|7|FT|X433^Organism 1|1|METHICILLIN RESISTANT\.br\STAPHYLOCOCCUS AUREUS     HEAVY GROWTH\.br\- Methicillin-resistant Staph aureus\.br\confirmed by PCR\.br\||||||F|||20130909135015
OBX|8|ST|6932-8^Penicillin|1|R||||||F|||20130909135015
OBX|9|ST|197-4^Cloxacillin|1|R||||||F|||20130909135015
OBX|10|ST|X10042^Cephalothin-Cephalexin|1|R||||||F|||20130909135015
OBX|11|ST|233-7^Erythromycin|1|S||||||F|||20130909135015
OBX|12|ST|193-3^Clindamycin|1|S||||||F|||20130909135015
OBX|13|ST|516-5^Trimethoprim-Sulfa|1|S||||||F|||20130909135015
OBX|14|ST|185-9^Ciprofloxacin|1|S||||||F|||20130909135015
OBX|15|ST|496-0^Tetracycline|1|S||||||F|||20130909135015
OBX|16|ST|524-9^Vancomycin|1|S||||||F|||20130909135015
OBX|17|FT|X10019^Organism 2|2|STENOTROPHOMONAS (XANTHOMONAS)\.br\MALTOPHILIA     LIGHT GROWTH\.br\||||||F|||20130909135015
OBX|18|ST|516-5^Trimethoprim-Sulfa|2|S||||||F|||20130909135015
OBX|19|ST|20396-8^Levofloxacin|2|S||||||F|||20130909135015
]]></Message><Message MsgID="7"><![CDATA[MSH|^~\&|PATHL7|VML|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551210|P|2.3|||ER|AL
PID||9130913913|||EXCELLERIS^CPATIENT||19240817|F|||||(250)555-5555
ORC|RE||139900026-HP-0|||||||||90909^MDCARE^BOB
OBR|1||139900026-HP-0|HP^Hematology Panel|R|20130905115924|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905143605||HAEM1|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|12227-5^WBC||7.6|*10E 9/L|4.0 - 10.0|N|||F|||20130905143603
OBX|2|NM|789-8^RBC||4.97|*10E12/L|4.20 - 5.40|N|||F|||20130905143557
OBX|3|NM|718-7^Hemoglobin||155|g/L|120 - 160|N|||F|||20130905143558
OBX|4|NM|4544-3^Hematocrit||0.445|L/L|0.370 - 0.470|N|||F|||20130905143558
OBX|5|NM|787-2^MCV||90|fl|80 - 97|N|||F|||20130905143558
OBX|6|NM|785-6^MCH||31.2|pg|27.0 - 31.0|H|||F|||20130905143559
OBX|7|NM|786-4^MCHC||348|g/L|320 - 360|N|||F|||20130905143559
OBX|8|NM|777-3^Platelet Count||263|*10E 9/L|150 - 400|N|||F|||20130905143559
OBX|9|NM|751-8^Neutrophils||5.2|*10E 9/L|2.0 - 7.5|N|||F|||20130905143603
OBX|10|NM|731-0^Lymphocytes||1.6|*10E 9/L|1.5 - 4.0|N|||F|||20130905143604
OBX|11|NM|742-7^Monocytes||0.4|*10E 9/L|0.2 - 0.8|N|||F|||20130905143604
OBX|12|NM|711-2^Eosinophils||0.3|*10E 9/L|0.0 - 0.4|N|||F|||20130905143605
OBX|13|NM|704-7^Basophils||0.0|*10E 9/L|0.0 - 0.1|N|||F|||20130905143605
ORC|RE||139900026-PT-0|||||||||90909^MDCARE^BOB
OBR|2||139900026-PT-0|PT^INR|R|20130905115926|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145924||HAEM3|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|6301-6^INR||1.1|||N|||F|||20130905145924
ORC|RE||139900026-IBR-0|||||||||90909^MDCARE^BOB
OBR|3||139900026-IBR-0|IBR^Iron / TIBC|R|20130905115926|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145934||CHEM1|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|14798-3^Iron||20|umol/L|6 - 31|N|||F|||20130905145931
OBX|2|NM|14800-7^TIBC||66|umol/L|35 - 70|N|||F|||20130905145934
OBX|3|NM|14801-5^Iron Saturation||0.30||0.20 - 0.45|N|||F|||20130905145934
ORC|RE||139900026-FRT-0|||||||||90909^MDCARE^BOB
OBR|4||139900026-FRT-0|FRT^Ferritin|R|20130905115505|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905151445||CHEM1|F||^^^^^R|90909^MDCARE^BOB
NTE|||FERRITIN\.br\Borderline Iron Deficiency    20 - 40 ug/L\.br\Iron Deficiency                    <20       ug/L
OBX|1|NM|2276-4^Ferritin||38.8|ug/L|40.0 - 200.0|L|||F|||20130905151445
ORC|RE||139900026-FBS-0|||||||||90909^MDCARE^BOB
OBR|5||139900026-FBS-0|FBS^Glucose Fasting|R|20130905115539|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145729||CHEM4|F||^^^^^R|90909^MDCARE^BOB
NTE|||Hrs. Fasting = 15
OBX|1|NM|14771-0^Glucose Fasting||5.5|mmol/L|3.9 - 6.0|N|||F|||20130905145729
ORC|RE||139900026-A1C-0|||||||||90909^MDCARE^BOB
OBR|6||139900026-A1C-0|A1C^Hemoglobin A1c|R|20130905115927|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130906105132||CHEM4|F||^^^^^R|90909^MDCARE^BOB
NTE|||A1C\.br\For diagnosis of diabetes,  A1C  >= 6.5%  (ADA 2010)\.br\\.br\A1C target for diabetes glycemic control : <= 7.0%  (CDA 2008)\.br\(Equivalent to 3MABG <= 8.5 mmol/L)
OBX|1|NM|4548-4^Hemoglobin A1c||6.1|%|SEE COMMENT|N|||F|||20130906105132
OBX|2|NM|53553-4^3 month Average Blood Glucose||7.1|mmol/L|<8.5|N|||F|||20130906105132
ORC|RE||139900026-LYTE-0|||||||||90909^MDCARE^BOB
OBR|7||139900026-LYTE-0|LYTE^Electrolytes|R|20130905115548|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145414||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|2951-2^Sodium||141|mmol/L|135 - 145|N|||F|||20130905144941
OBX|2|NM|2823-3^Potassium||4.3|mmol/L|3.5 - 5.0|N|||F|||20130905144938
OBX|3|NM|2075-0^Chloride||103|mmol/L|98 - 109|N|||F|||20130905144936
OBX|4|NM|1963-8^Bicarbonate||24|mmol/L|23 - 28|N|||F|||20130905145408
OBX|5|NM|33037-3^Anion Gap||14|mmol/L|5 - 14|N|||F|||20130905145414
ORC|RE||139900026-CRE-0|||||||||90909^MDCARE^BOB
OBR|8||139900026-CRE-0|CRE^Creatinine/eGFR|R|20130905115927|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145746||CHEM4|F||^^^^^R|90909^MDCARE^BOB
NTE|||eGFR GUIDE.....GPAC`04\.br\-eGFR <30 or persistent abn. urine or Alb/Creat Ratio (ACR)...Refer\.br\-isolated eGFR 30 - 60 monitor eGFR, ACR q6/12\.br\-isolated eGFR 60 - 90 monitor eGFR, ACR yearly\.br\SEE GUIDELINE FOR DETAILS REGARDING FURTHER INVESTIGATION/MANAGEMENT
OBX|1|NM|14682-9^Creatinine||54|umol/L|52 - 84|N|||F|||20130905145732
OBX|2|NM|33914-3^Estimated GFR||124|ml/min|SEE COMMENT|N|||F|||20130905145746
ORC|RE||139900026-CA-0|||||||||90909^MDCARE^BOB
OBR|9||139900026-CA-0|CA^Calcium|R|20130905115523|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145223||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|2000-8^Calcium||2.30|mmol/L|2.12 - 2.62|N|||F|||20130905145223
ORC|RE||139900026-PO4-0|||||||||90909^MDCARE^BOB
OBR|10||139900026-PO4-0|PO4^Phosphorus|R|20130905115522|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145745||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|14879-1^Phosphorus||0.99|mmol/L|0.80 - 1.45|N|||F|||20130905145745
ORC|RE||139900026-ALB-0|||||||||90909^MDCARE^BOB
OBR|11||139900026-ALB-0|ALB^Albumin|R|20130905115518|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145302||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|1751-7^Albumin||45|g/L|35 - 50|N|||F|||20130905145302
ORC|RE||139900026-BIL-0|||||||||90909^MDCARE^BOB
OBR|12||139900026-BIL-0|BIL^Bilirubin|R|20130905115526|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145500||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|14631-6^Total Bilirubin||20|umol/L|<17|H|||F|||20130905145500
ORC|RE||139900026-ALK-0|||||||||90909^MDCARE^BOB
OBR|13||139900026-ALK-0|ALK^Alkaline Phosphatase|R|20130905115528|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145806||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|6768-6^Alkaline Phosphatase||120|U/L|<105|H|||F|||20130905145806
ORC|RE||139900026-YGT-0|||||||||90909^MDCARE^BOB
OBR|14||139900026-YGT-0|YGT^Gamma GT|R|20130905115531|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145845||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|2324-2^Gamma GT||9|U/L|<55|N|||F|||20130905145845
ORC|RE||139900026-ALT-0|||||||||90909^MDCARE^BOB
OBR|15||139900026-ALT-0|ALT^ALT|R|20130905115533|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145849||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|1742-6^ALT||17|U/L|<30|N|||F|||20130905145849
ORC|RE||139900026-AST-0|||||||||90909^MDCARE^BOB
OBR|16||139900026-AST-0|AST^AST|R|20130905115529|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145808||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|1920-8^AST||20|U/L|<30|N|||F|||20130905145808
ORC|RE||139900026-LDH-0|||||||||90909^MDCARE^BOB
OBR|17||139900026-LDH-0|LDH^Lactate Dehydrogenase|R|20130905115532|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145736||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|14805-6^Lactate Dehydrogenase||343|U/L|<480|N|||F|||20130905145736
ORC|RE||139900026-MG-0|||||||||90909^MDCARE^BOB
OBR|18||139900026-MG-0|MG^Magnesium|R|20130905115520|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145410||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|2601-3^Magnesium||0.88|mmol/L|0.70 - 1.00|N|||F|||20130905145410
ORC|RE||139900026-AMY-0|||||||||90909^MDCARE^BOB
OBR|19||139900026-AMY-0|AMY^Amylase|R|20130905115525|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905145847||CHEM4|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|1798-8^Amylase||62|U/L|<110|N|||F|||20130905145847
ORC|RE||139900026-LIP-0|||||||||90909^MDCARE^BOB
OBR|20||139900026-LIP-0|LIP^Lipids|R|20130905115930|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905153256||CHEM6|F||^^^^^R|90909^MDCARE^BOB
NTE|||Hrs. Fasting = 15
OBX|1|NM|14647-2^Cholesterol||2.92|mmol/L|<4.60|N|||F|||20130905153245
OBX|2|NM|39469-2^LDL Cholesterol||1.1|mmol/L|<3.40|N|||F|||20130905153255
OBX|3|NM|14646-4^HDL Cholesterol||1.20|mmol/L|>0.90|N|||F|||20130905145934
OBX|4|NM|32309-7^Chol/HDL (Risk Ratio)||2.4||<4.7|N|||F|||20130905153256
OBX|5|NM|14927-8^Triglycerides||1.30|mmol/L|<2.26|N|||F|||20130905145503
ORC|RE||139900026-IGE-0|||||||||90909^MDCARE^BOB
OBR|21||139900026-IGE-0|IGE^IgE|R|20130905115606|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130906083018||CHEM17|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|2462-0^IgE||16|ug/L|<423|N|||F|||20130906083018
ORC|RE||139900026-VITA-0|||||||||90909^MDCARE^BOB
OBR|22||139900026-VITA-0|VITA^Vitamin A|R|20130905115602|20130905114831|||||||20130905114831||90909^MDCARE^BOB||||||20130905115950||REFER1|F||^^^^^R|90909^MDCARE^BOB
NTE|||Sent to BC Childrens Hospital. For inquiries call 604-875-2345.\.br\Result to Follow.
OBX|1|ST|X500^Referred Test||.|||N|||F|||20130905115950
]]></Message><Message MsgID="8"><![CDATA[MSH|^~\&|PATHL7|FHAM|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551211|P|2.3|||ER|AL
PID||9050505050|PA00000025||EXCELLERIS^GGPATIENT||19480918|F|||||(604)588-1236
ORC|RE||13-90004009-HP-2305|||||||||90909^MDCARE^BOB
OBR|1||13-90004009-HP-2305|HP^Hematology Panel||20130909144500|20130909145000|||||||20130909154100||90909^MDCARE^BOB||||||20130909181700||HAEM1|F|||90909^MDCARE^BOB
OBX|1|ST|12227-5^WBC||4.8|x10*9/L|4.0-11.0|N|||F|||20130909181700
OBX|2|ST|789-8^RBC||1.98|x10*12/L|3.50-5.00|L|||F|||20130909181700
OBX|3|ST|718-7^Hemoglobin||59|g/L|115-160|L|||F|||20130909163200
OBX|4|ST|4544-3^Hematocrit||0.17|L/L|0.35-0.47|L|||F|||20130909181700
OBX|5|ST|787-2^MCV||86|fL|80-100|N|||F|||20130909181700
OBX|6|TX|777-3^Platelet Count||Platelet Count not available. Refer to platelet estimate.|x10*9/L|150-400|N|||F|||20130909181700
OBX|7|ST|751-8^Neutrophils||2.4|x10*9/L|2.0-8.0|N|||F|||20130909181700
OBX|8|ST|731-0^Lymphocytes||2.4|x10*9/L|1.0-4.0|N|||F|||20130909181700
OBX|9|ST|742-7^Monocytes||< 0.1|x10*9/L|0.1-0.8|L|||F|||20130909181700
OBX|10|ST|711-2^Eosinophils||< 0.1|x10*9/L|<0.6|N|||F|||20130909181700
OBX|11|ST|704-7^Basophils||< 0.1|x10*9/L|<0.2|N|||F|||20130909181700
OBX|12|ST|9317-9^Platelet Estimate||Normal Number|||N|||F|||20130909181700
OBX|13|ST|7796-6^Platelet Clumps||Present|||H|||F|||20130909181700
ORC|RE||13-90004009-TMR-166|||||||||90909^MDCARE^BOB
OBR|2||13-90004009-TMR-166|TMR^Transfusion Medicine Report|R||20130909145000|||KSHAH||||20130909154100||90909^MDCARE^BOB||||||20130909193300||BLOOKBANKT|F||^^^^^R|90909^MDCARE^BOB
OBX|1|TX|XXX-1926^Transfusion Medicine Report|1|Specimen: 0909:T00166R                  Status: COMP||||||F|||20130909193300
OBX|2|TX|XXX-1926^Transfusion Medicine Report|2|Ordered Prods: (NO ORDERED PRODUCTS)||||||F|||20130909193300
OBX|3|TX|XXX-1926^Transfusion Medicine Report|3|Ordered Tests: EXTRA SAMPLETML, Group \T\ Screen, Grp \T\ Scr Tests||||||F|||20130909193300
OBX|4|TX|XXX-1926^Transfusion Medicine Report|4|> EXTRA SAMPLETML        EXTRA TML SAMPLE||||||F|||20130909193300
OBX|5|TX|XXX-1926^Transfusion Medicine Report|5|                          Sample received by Transfusion Medicine Laboratory.||||||F|||20130909193300
OBX|6|TX|XXX-1926^Transfusion Medicine Report|6|                          Tests will be added and performed as required.||||||F|||20130909193300
OBX|7|TX|XXX-1926^Transfusion Medicine Report|7|> ABO/Rh Bld Grp         O POS||||||F|||20130909193300
OBX|8|TX|XXX-1926^Transfusion Medicine Report|8|> Antibody Screen        NEGATIVE||||||F|||20130909193300
OBX|9|TX|XXX-1926^Transfusion Medicine Report|9|--------------------------------------------------------------------------------------------||||||F|||20130909193300
OBX|10|TX|XXX-1926^Transfusion Medicine Report|10|||||||F|||20130909193300
OBX|11|TX|XXX-1926^Transfusion Medicine Report|11|||||||F|||20130909193300
OBX|12|TX|XXX-1926^Transfusion Medicine Report|12|||||||F|||20130909193300
OBX|13|TX|XXX-1926^Transfusion Medicine Report|13|||||||F|||20130909193300
OBX|14|TX|XXX-1926^Transfusion Medicine Report|14|||||||F|||20130909193300
OBX|15|TX|XXX-1926^Transfusion Medicine Report|15|||||||F|||20130909193300
OBX|16|TX|XXX-1926^Transfusion Medicine Report|16|||||||F|||20130909193300
OBX|17|TX|XXX-1926^Transfusion Medicine Report|17|||||||F|||20130909193300
OBX|18|TX|XXX-1926^Transfusion Medicine Report|18|||||||F|||20130909193300
OBX|19|TX|XXX-1926^Transfusion Medicine Report|19|||||||F|||20130909193300
OBX|20|TX|XXX-1926^Transfusion Medicine Report|20|||||||F|||20130909193300
OBX|21|TX|XXX-1926^Transfusion Medicine Report|21|||||||F|||20130909193300
OBX|22|TX|XXX-1926^Transfusion Medicine Report|22|||||||F|||20130909193300
OBX|23|TX|XXX-1926^Transfusion Medicine Report|23|||||||F|||20130909193300
OBX|24|TX|XXX-1926^Transfusion Medicine Report|24|||||||F|||20130909193300
OBX|25|TX|XXX-1926^Transfusion Medicine Report|25|||||||F|||20130909193300
OBX|26|TX|XXX-1926^Transfusion Medicine Report|26|||||||F|||20130909193300
OBX|27|TX|XXX-1926^Transfusion Medicine Report|27|||||||F|||20130909193300
OBX|28|TX|XXX-1926^Transfusion Medicine Report|28|||||||F|||20130909193300
OBX|29|TX|XXX-1926^Transfusion Medicine Report|29|||||||F|||20130909193300
]]></Message><Message MsgID="9"><![CDATA[MSH|^~\&|PATHL7|BCB|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551212|P|2.3|||ER|AL
PID||9101321654|||EXCELLERIS^BPATIENT||19430102|F|||||604-658-2107
ORC|RE||13-9190039-HP-0|||||||||90909^MDCARE^BOB
OBR|1||13-9190039-HP-0|HP^Hematology Panel||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910150700||HAEM1|F|||90909^MDCARE^BOB
OBX|1|NM|12227-5^WBC||7.9|10*9/L|4.0 - 11.0||||F|||20130910150700
OBX|2|NM|789-8^RBC||3.73|10*12/L|3.50 - 5.00||||F|||20130910150700
OBX|3|NM|718-7^Hemoglobin||94|g/L|115 - 160|L|||F|||20130910150700
OBX|4|NM|4544-3^Hematocrit||0.31|L/L|0.35 - 0.47|L|||F|||20130910150700
OBX|5|NM|787-2^MCV||83|fL|80 - 100||||F|||20130910150700
OBX|6|NM|785-6^MCH||25.2|pg|27.0 - 34.0|L|||F|||20130910150700
OBX|7|NM|786-4^MCHC||302|g/L|315 - 365|L|||F|||20130910150700
OBX|8|NM|777-3^Platelet Count||322|10*9/L|150 - 400||||F|||20130910150700
OBX|9|NM|26499-4^Neutrophils||5.4|10*9/L|2.0 - 8.0||||F|||20130910150700
OBX|10|NM|26474-7^Lymphocytes||1.6|10*9/L|1.0 - 4.0||||F|||20130910150700
OBX|11|NM|26484-6^Monocytes||0.6|10*9/L|< 0.9||||F|||20130910150700
OBX|12|NM|26449-9^Eosinophils||0.2|10*9/L|< 0.8||||F|||20130910150700
OBX|13|NM|26444-0^Basophils||0.0|10*9/L|< 0.3||||F|||20130910150700
OBX|14|NM|51584-1^Granulocytes Immature||0.0|10*9/L|< 0.2||||F|||20130910150700
OBX|15|TX|10378-8^Polychromasia||1+||||||F|||20130910150700
ORC|RE||13-9190039-IBR-0|||||||||90909^MDCARE^BOB
OBR|2||13-9190039-IBR-0|IBR^Iron / TIBC||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910133100||CHEM1|F|||90909^MDCARE^BOB
OBX|1|NM|14798-3^Iron||8|umol/L|9-30|L|||F|||20130910133100
OBX|2|NM|14800-7^TIBC||70|umol/L|45 - 70||||F|||20130910133100
OBX|3|NM|14801-5^Iron Saturation||0.11||0.15 - 0.55|L|||F|||20130910133100
ORC|RE||13-9190039-FRT-0|||||||||90909^MDCARE^BOB
OBR|3||13-9190039-FRT-0|FRT^Ferritin||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910142900||CHEM1|F|||90909^MDCARE^BOB
OBX|1|NM|2276-4^Ferritin||7|ug/L|> 14|L|||F|||20130910142900
NTE|||\.br\Interpretation: \.br\<15 ug/L-diagnostic of iron deficiency\.br\15-49 ug/L-probable iron deficiency\.br\50-100 ug/L-possible iron deficiency\.br\>100 ug/L-iron deficiency unlikely. If result\.br\is persistently >1000 ug/L, consider\.br\test for iron overload (transferrin\.br\saturation).
ORC|RE||13-9190039-FBS-0|||||||||90909^MDCARE^BOB
OBR|4||13-9190039-FBS-0|FBS^Glucose Fasting||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|14771-0^Glucose Fasting||4.9|mmol/L|3.6 - 5.5||||F|||20130910141700
OBX|2|NM|55420-4^Hours After Meal||13.6|h pc|||||F|||20130910074100
OBX|3|TX|19151-0^Specimen Drawn||0745|h|||||F|||20130910074100
ORC|RE||13-9190039-A1C-0|||||||||90909^MDCARE^BOB
OBR|5||13-9190039-A1C-0|A1C^Hemoglobin A1c||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910171800||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|4548-4^Hemoglobin A1c||6.2|%|4.8 - 6.2||||F|||20130910171800
NTE|||The BCMA/MSP Clinical Practice Guideline "Diabetes\.br\Care" (for non-pregnant adults) recommends A1C\.br\measurements no more frequently than every 3\.br\months.\.br\\.br\Result assumes normal red cell lifespan and\.br\absence of hemoglobinopathy.
ORC|RE||13-9190039-LYTE-0|||||||||90909^MDCARE^BOB
OBR|6||13-9190039-LYTE-0|LYTE^Electrolytes||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|2951-2^Sodium||143|mmol/L|135 - 145||||F|||20130910141700
OBX|2|NM|2823-3^Potassium||4.2|mmol/L|3.5 - 5.0||||F|||20130910141700
OBX|3|NM|2075-0^Chloride||105|mmol/L|98 - 108||||F|||20130910141700
OBX|4|NM|1963-8^Bicarbonate||26|mmol/L|20 - 30||||F|||20130910141700
ORC|RE||13-9190039-BUN-0|||||||||90909^MDCARE^BOB
OBR|7||13-9190039-BUN-0|BUN^Urea||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|22664-7^Urea||6.7|mmol/L|2.0 - 9.0||||F|||20130910141700
ORC|RE||13-9190039-CRE-0|||||||||90909^MDCARE^BOB
OBR|8||13-9190039-CRE-0|CRE^Creatinine/eGFR||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|14682-9^Creatinine||91|umol/L|45 - 90|H|||F|||20130910141700
OBX|2|NM|33914-3^Estimated GFR||53|mL/min/1.73sq.m|> 59|L|||F|||20130910141700
NTE|||Note: eGFR based on serum creatinine, age and gender. This\.br\result indicates reduced function, needs further\.br\evaluation and follow up: see\.br\www.healthservices.gov.bc.ca/msp/protoguides/gps/ckd.pdf
ORC|RE||13-9190039-CA-0|||||||||90909^MDCARE^BOB
OBR|9||13-9190039-CA-0|CA^Calcium||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|2000-8^Calcium||2.18|mmol/L|2.10 - 2.60||||F|||20130910141700
NTE|||Note: New Calcium Reagent Formulation\.br\effective Aug 14, 2013.\.br\(Roche Photometric, NM-BAPTA)
ORC|RE||13-9190039-PO4-0|||||||||90909^MDCARE^BOB
OBR|10||13-9190039-PO4-0|PO4^Phosphorus||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|14879-1^Phosphorus||1.2|mmol/L|0.8 - 1.5||||F|||20130910141700
ORC|RE||13-9190039-ALB-0|||||||||90909^MDCARE^BOB
OBR|11||13-9190039-ALB-0|ALB^Albumin||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|1751-7^Albumin||40|g/L|35 - 50||||F|||20130910141700
ORC|RE||13-9190039-ALK-0|||||||||90909^MDCARE^BOB
OBR|12||13-9190039-ALK-0|ALK^Alkaline Phosphatase||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|6768-6^Alkaline Phosphatase||89|U/L|35 - 120||||F|||20130910141700
ORC|RE||13-9190039-AST-0|||||||||90909^MDCARE^BOB
OBR|13||13-9190039-AST-0|AST^AST||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|1920-8^AST||11|U/L|< 36||||F|||20130910141700
ORC|RE||13-9190039-LIP-0|||||||||90909^MDCARE^BOB
OBR|14||13-9190039-LIP-0|LIP^Lipids||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910141700||CHEM6|F|||90909^MDCARE^BOB
OBX|1|NM|14647-2^Cholesterol||4.94|mmol/L|2.00 - 5.20||||F|||20130910141700
NTE|||At risk:>6.20   mmol/L
OBX|2|NM|39469-2^LDL Cholesterol||2.51|mmol/L|1.50 - 3.40||||F|||20130910141700
NTE|||At risk:>3.40   mmol/L\.br\An LDL cholesterol level of less than 2.60 mmol/L\.br\is suggested for patients with established CAD.
OBX|3|NM|14646-4^HDL Cholesterol||1.93|mmol/L|> 1.19||||F|||20130910141700
OBX|4|NM|32309-7^Chol/HDL (Risk Ratio)||2.56||< 4.31||||F|||20130910141700
NTE|||A ratio of 4.40 in females is associated with\.br\average risk. Increased ratios are associated\.br\with higher risk for CAD.
OBX|5|NM|14927-8^Triglycerides||1.10|mmol/L|< 2.21||||F|||20130910141700
OBX|6|NM|55420-4^Hours After Meal||13.6|h pc|||||F|||20130910074100
ORC|RE||13-9190039-RMA-0|||||||||90909^MDCARE^BOB
OBR|15||13-9190039-RMA-0|RMA^Urine Albumin Random||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910164900||CHEM10|F|||90909^MDCARE^BOB
NTE|||\.br\Note: Reference interval for albumin/creatinine ratio\.br\as per BCMA/ MSC guidelines.
OBX|1|NM|32294-1^Urine ACR (Albumin/Creatinine Ratio)||0.8|mg/mmol Creat.|< 2.8||||F|||20130910164900
OBX|2|TX|41395-5^Collection Date||13/09/10|YY/MM/DD|||||F|||20130910074100
ORC|RE||13-9190039-PTH-0|||||||||90909^MDCARE^BOB
OBR|16||13-9190039-PTH-0|PTH^Parathyroid Hormone||20130910074000|20130910074000|||||||20130910074000||90909^MDCARE^BOB||131815939||||20130910144600||CHEM28|F|||90909^MDCARE^BOB
NTE|||Note: Intact PTH performed at BC Biomedical.\.br\Results from other laboratories can vary due to\.br\differences in assay methods.
OBX|1|NM|14866-8^Parathyroid Hormone Intact||7.5|pmol/L|1.6 - 6.9|H|||F|||20130910144500
NTE|||(Roche-Electrochemiluminescence)
OBX|2|NM|55420-4^Hours After Meal||13.6|h pc|||||F|||20130910074100
OBX|3|TX|19151-0^Drawn At||0745|h|||||F|||20130910074100
]]></Message><Message MsgID="10"><![CDATA[MSH|^~\&|PATHL7|FHAM|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551213|P|2.3|||ER|AL
PID||9876432456|RC00000083||EXCELLERIS^GPATIENT||19750926|M|||||(604)687-7507
ORC|RE||13-QA999881-CYTGR-0|||||||||90909^MDCARE^BOB
OBR|1||13-QA999881-CYTGR-0|CYTGR^Cytogenetics Report|||20130911|||||||20130911143300||90909^MDCARE^BOB||||||20130918125500||CELLPATH|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|TX|XXX-1930^Cytogenetics Report|1|Molecular Cytogenetics Lab: Royal Columbian Hospital||||||F|||20130918125500
OBX|2|TX|XXX-1930^Cytogenetics Report|2|Phone: (604)520-4484 Fax: (604)520-4149||||||F|||20130918125500
OBX|3|TX|XXX-1930^Cytogenetics Report|3|||||||F|||20130918125500
OBX|4|TX|XXX-1930^Cytogenetics Report|4|Specimen Number: 13RG-2105||||||F|||20130918125500
OBX|5|TX|XXX-1930^Cytogenetics Report|5|||||||F|||20130918125500
OBX|6|TX|XXX-1930^Cytogenetics Report|6|FINAL DIAGNOSES||||||F|||20130918125500
OBX|7|TX|XXX-1930^Cytogenetics Report|7|Cytogenetic Diagnosis:  Normal Male||||||F|||20130918125500
OBX|8|TX|XXX-1930^Cytogenetics Report|8|||||||F|||20130918125500
OBX|9|TX|XXX-1930^Cytogenetics Report|9|||||||F|||20130918125500
OBX|10|TX|XXX-1930^Cytogenetics Report|10|Cytogenetic analysis of the cultured bone marrow specimen reveals a normal male karyotype at||||||F|||20130918125500
OBX|11|TX|XXX-1930^Cytogenetics Report|11|the achieved band level resolution of 300-350.  No evidence of a cell line with an abnormal||||||F|||20130918125500
OBX|12|TX|XXX-1930^Cytogenetics Report|12|chromosomal complement is found.||||||F|||20130918125500
OBX|13|TX|XXX-1930^Cytogenetics Report|13|||||||F|||20130918125500
OBX|14|TX|XXX-1930^Cytogenetics Report|14|||||||F|||20130918125500
OBX|15|TX|XXX-1930^Cytogenetics Report|15|ISCN:||||||F|||20130918125500
OBX|16|TX|XXX-1930^Cytogenetics Report|16|||||||F|||20130918125500
OBX|17|TX|XXX-1930^Cytogenetics Report|17|46,XY[25]||||||F|||20130918125500
OBX|18|TX|XXX-1930^Cytogenetics Report|18|||||||F|||20130918125500
OBX|19|TX|XXX-1930^Cytogenetics Report|19|||||||F|||20130918125500
OBX|20|TX|XXX-1930^Cytogenetics Report|20|Metaphase Cells: 25||||||F|||20130918125500
OBX|21|TX|XXX-1930^Cytogenetics Report|21|B.L.R.: 300-350||||||F|||20130918125500
OBX|22|TX|XXX-1930^Cytogenetics Report|22|||||||F|||20130918125500
OBX|23|TX|XXX-1930^Cytogenetics Report|23|SPECIMEN SUBMITTED||||||F|||20130918125500
OBX|24|TX|XXX-1930^Cytogenetics Report|24|Bone Marrow.||||||F|||20130918125500
OBX|25|TX|XXX-1930^Cytogenetics Report|25|||||||F|||20130918125500
OBX|26|TX|XXX-1930^Cytogenetics Report|26|||||||F|||20130918125500
OBX|27|TX|XXX-1930^Cytogenetics Report|27|||||||F|||20130918125500
OBX|28|TX|XXX-1930^Cytogenetics Report|28|CLINICAL INFORMATION||||||F|||20130918125500
OBX|29|TX|XXX-1930^Cytogenetics Report|29|Bone Marrow Diagnosis:  Consistent with myelodysplastic syndrome, best classified as||||||F|||20130918125500
OBX|30|TX|XXX-1930^Cytogenetics Report|30|refractory cytopenia with multilineage dysplasia.||||||F|||20130918125500
OBX|31|TX|XXX-1930^Cytogenetics Report|31|                                                    ____________________________________||||||F|||20130918125500
OBX|32|TX|XXX-1930^Cytogenetics Report|32|                                                    M. H., MD FRCPC FCCMG||||||F|||20130918125500
OBX|33|TX|XXX-1930^Cytogenetics Report|33|                                                    Electronically signed: 18/Sep/2013||||||F|||20130918125500
OBX|34|TX|XXX-1930^Cytogenetics Report|34|||||||F|||20130918125500
OBX|35|TX|XXX-1930^Cytogenetics Report|35|--------------------------------------------------------------------------------------------||||||F|||20130918125500
]]></Message><Message MsgID="11"><![CDATA[MSH|^~\&|PATHL7|VCH|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551214|P|2.3|||ER|AL
PID||9080060306|402474||EXCELLERIS^FPATIENT||19210523|F|||||604-878-2669
ORC|RE||QA13-99957-AP9995802-SPR-1|||||||||90909^MDCARE^BOB
OBR|1||QA13-99957-AP9995802-SPR-1|SPR^Surgical Pathology Report|||20130911000000|||||||20130911142700||90909^MDCARE^BOB||||||20130917085100||CELLPATH|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|FT|27898-6^Pathology Studies|1|\.br\||||||F|||20130917085100
OBX|2|FT|27898-6^Pathology Studies|2|\.br\||||||F|||20130917085100
OBX|3|FT|27898-6^Pathology Studies|3|VANCOUVER COASTAL HEALTH||||||F|||20130917085100
OBX|4|FT|27898-6^Pathology Studies|4|LIONS GATE HOSPITAL||||||F|||20130917085100
OBX|5|FT|27898-6^Pathology Studies|5|Department of Laboratory Medicine||||||F|||20130917085100
OBX|6|FT|27898-6^Pathology Studies|6|231 E. 15th St. North Vancouver, BC V7L 2L7||||||F|||20130917085100
OBX|7|FT|27898-6^Pathology Studies|7|Inquiry TEL 1-877-747-2522,   Fax  604-984-5805||||||F|||20130917085100
OBX|8|FT|27898-6^Pathology Studies|8|\.br\||||||F|||20130917085100
OBX|9|FT|27898-6^Pathology Studies|9|Surgical Pathology Report||||||F|||20130917085100
OBX|10|FT|27898-6^Pathology Studies|10|\.br\||||||F|||20130917085100
OBX|11|FT|27898-6^Pathology Studies|11|Case Number  :     QA13-99957    EXCELLERIS, FPATIENT||||||F|||20130917085100
OBX|12|FT|27898-6^Pathology Studies|12|Location     :     Lions Gate Day Care Surgery||||||F|||20130917085100
OBX|13|FT|27898-6^Pathology Studies|13|PHN          :     9080060306          Encounter :13142388\E\0402474\E\3\E\5\E\1||||||F|||20130917085100
OBX|14|FT|27898-6^Pathology Studies|14|Collect Date :     Sep 11, 2013     Med Rec   :     0402474||||||F|||20130917085100
OBX|15|FT|27898-6^Pathology Studies|15|Receive Date :     Sep 11, 2013     DOB/Gender:     May 23, 1921  92Y F||||||F|||20130917085100
OBX|16|FT|27898-6^Pathology Studies|16|Date Reported:     Sep 17, 2013     OrdPhys   :     L.M., MD||||||F|||20130917085100
OBX|17|FT|27898-6^Pathology Studies|17|\.br\||||||F|||20130917085100
OBX|18|FT|27898-6^Pathology Studies|18|\.br\||||||F|||20130917085100
OBX|19|FT|27898-6^Pathology Studies|19|Final Diagnosis ::||||||F|||20130917085100
OBX|20|FT|27898-6^Pathology Studies|20|Endometrium, curettings -||||||F|||20130917085100
OBX|21|FT|27898-6^Pathology Studies|21|Benign proliferative-type endometrium.  Negative for glandular hyperplasia and||||||F|||20130917085100
OBX|22|FT|27898-6^Pathology Studies|22|negative for cytologic atypia.||||||F|||20130917085100
OBX|23|FT|27898-6^Pathology Studies|23|\.br\||||||F|||20130917085100
OBX|24|FT|27898-6^Pathology Studies|24|RAW/cm||||||F|||20130917085100
OBX|25|FT|27898-6^Pathology Studies|25|\.br\||||||F|||20130917085100
OBX|26|FT|27898-6^Pathology Studies|26|Electronically signed by W.R.A.||||||F|||20130917085100
OBX|27|FT|27898-6^Pathology Studies|27|September 17, 2013  08:51:45||||||F|||20130917085100
OBX|28|FT|27898-6^Pathology Studies|28|\.br\||||||F|||20130917085100
OBX|29|FT|27898-6^Pathology Studies|29|Clinical History as Provided by Submitting Physician ::||||||F|||20130917085100
OBX|30|FT|27898-6^Pathology Studies|30|menorrhagia||||||F|||20130917085100
OBX|31|FT|27898-6^Pathology Studies|31|\.br\||||||F|||20130917085100
OBX|32|FT|27898-6^Pathology Studies|32|\.br\||||||F|||20130917085100
OBX|33|FT|27898-6^Pathology Studies|33|Specimen(s) Received ::||||||F|||20130917085100
OBX|34|FT|27898-6^Pathology Studies|34|Tissue, endometrium||||||F|||20130917085100
OBX|35|FT|27898-6^Pathology Studies|35|\.br\||||||F|||20130917085100
OBX|36|FT|27898-6^Pathology Studies|36|\.br\||||||F|||20130917085100
OBX|37|FT|27898-6^Pathology Studies|37|Gross Description ::||||||F|||20130917085100
OBX|38|FT|27898-6^Pathology Studies|38|Received is a single container labelled with the patient's name, EXCELLERIS, FPATIENT,||||||F|||20130917085100
OBX|39|FT|27898-6^Pathology Studies|39|demographics and ENDOMETRIUM.  It contains numerous fragments of hemorrhagic||||||F|||20130917085100
OBX|40|FT|27898-6^Pathology Studies|40|tissue aggregating to 4 cm.  Wrapped, submitted as A1 and A2.||||||F|||20130917085100
OBX|41|FT|27898-6^Pathology Studies|41|\.br\||||||F|||20130917085100
OBX|42|FT|27898-6^Pathology Studies|42|RS/mw||||||F|||20130917085100
OBX|43|FT|27898-6^Pathology Studies|43|\.br\||||||F|||20130917085100
OBX|44|FT|27898-6^Pathology Studies|44|\.br\||||||F|||20130917085100
OBX|45|FT|27898-6^Pathology Studies|45|Copies to:     M.L.M.     A.W.A.||||||F|||20130917085100
OBX|46|FT|27898-6^Pathology Studies|46|\.br\||||||F|||20130917085100
]]></Message><Message MsgID="12"><![CDATA[MSH|^~\&|PATHL7|CW|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551215|P|2.3|||ER|AL
PID||1008405002|1008405002||EXCELLERIS^PPATIENT||19830306|F|||||604-658-2332
ORC|RE||QA9925-28000080-URC-1|||||||||90909^MDCARE^BOB
OBR|1||QA9925-28000080-URC-1|URC^Urine Culture||20130911114200|20130911073000|||||||20130911114100||90909^MDCARE^BOB||||||20130913144808||MICRO3|P|||90909^MDCARE^BOB
OBX|1|FT|XXX-0002^Specimen Description||Urine||||||P|||20130911114307
OBX|2|FT|6463-4^Culture|1|1x10e7 cfu/L Escherichia coli 'Multi-drug resistant organism isolated' 'Further susceptibility results to follow.'||||||P|||20130913144808
OBX|3|FT|28-1^Ampicillin|1|R||||||P|||20130913144808
OBX|4|FT|149-5^Cephalexin|1|R||||||P|||20130913144808
OBX|5|FT|76-0^Cefazolin|1|R||||||P|||20130913144808
OBX|6|FT|80-2^Cefixime|1|R||||||P|||20130913144808
OBX|7|FT|108-1^Cefotaxime|1|R||||||P|||20130913144808
OBX|8|FT|516-5^Trimethoprim-Sulfa|1|S||||||P|||20130913144808
OBX|9|FT|267-5^Gentamicin|1|S||||||P|||20130913144808
OBX|10|FT|508-2^Tobramycin|1|R||||||P|||20130913144808
OBX|11|FT|363-2^Nitrofurantoin|1|S||||||P|||20130913144808
]]></Message><Message MsgID="13"><![CDATA[MSH|^~\&|PATHL7|LIFELABS|HTTPCLIENT|vendor1|20130927130551||ORU^R01|ACC20130927130551216|P|2.3|||ER|AL
PID||9055555555|||EXCELLERIS^APATIENT||19770726|M|||||(604)999-9999
ORC|RE||13-900900006-HP-1|||||||||90909^MDCARE^BOB
OBR|1||13-900900006-HP-1|HP^Hematology Panel||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||HAEM1|F|||90909^MDCARE^BOB
OBX|1|NM|6690-2^WBC||4.5|giga/L|4.0-10.0|N|||F|||20130911172003
OBX|2|NM|789-8^RBC||4.53|tera/L|4.20-5.40|N|||F|||20130911172003
OBX|3|NM|718-7^Hemoglobin||151|g/L|133-165|N|||F|||20130911172003
OBX|4|NM|4544-3^Hematocrit||0.43||0.38-0.50|N|||F|||20130911172003
OBX|5|NM|787-2^MCV||95|fl|82-98|N|||F|||20130911172003
OBX|6|NM|785-6^MCH||33.3|pg|27.5-33.5|N|||F|||20130911172003
OBX|7|NM|786-4^MCHC||352|g/L|305-365|N|||F|||20130911172003
OBX|8|NM|788-0^RDW||14.3|%|11.5-14.5|N|||F|||20130911172003
OBX|9|NM|777-3^Platelet Count||162|giga/L|150-400|N|||F|||20130911172003
OBX|10|NM|751-8^Neutrophils||2.3|giga/L|2.0-7.5|N|||F|||20130911172003
OBX|11|NM|731-0^Lymphocytes||1.4|giga/L|1.0-4.0|N|||F|||20130911172003
OBX|12|NM|742-7^Monocytes||0.5|giga/L|0.1-0.8|N|||F|||20130911172003
OBX|13|NM|711-2^Eosinophils||0.3|giga/L|0.0-0.7|N|||F|||20130911172003
OBX|14|NM|704-7^Basophils||0.0|giga/L|0.0-0.2|N|||F|||20130911172003
ORC|RE||13-900900006-UR-1|||||||||90909^MDCARE^BOB
OBR|2||13-900900006-UR-1|UR^Urine Chemistry/Micro||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM2|F|||90909^MDCARE^BOB
OBX|1|ST|5778-6^Colour||YELLOW||||||F|||20130911172003
OBX|2|ST|5767-9^Appearance||CLEAR||||||F|||20130911172003
OBX|3|NM|5803-2^pH||7.5||5.0-8.5|N|||F|||20130911172003
OBX|4|NM|5811-5^Specific Gravity||1.015||1.003-1.035|N|||F|||20130911172003
OBX|5|ST|5804-0^Protein||<0.3|g/L|<0.3|N|||F|||20130911172003
OBX|6|ST|22705-8^Glucose||<6|mmol/L|<6|N|||F|||20130911172003
OBX|7|ST|2514-8^Ketones||<1.5|mmol/L|<1.5|N|||F|||20130911172003
OBX|8|ST|5794-3^Hemoglobin||NEG||Neg|N|||F|||20130911172003
OBX|9|ST|5802-4^Nitrite||NEG||Neg|N|||F|||20130911172003
OBX|10|ST|5799-2^Leukocytes||NEG||Neg|N|||F|||20130911172003
OBX|11|FT|X10083^Test Comment||Criteria for microscopic analysis \.br\not met.\.br\\.br\||||||F|||20130911172003
ORC|RE||13-900900006-FBS-1|||||||||90909^MDCARE^BOB
OBR|3||13-900900006-FBS-1|FBS^Glucose Fasting||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|14771-0^Glucose Fasting||5.9|mmol/L|3.3-5.5|A|||F|||20130911172003
NTE|||Indicates increased risk of developing\.br\type 2 diabetes. Re-screen more often\.br\than every 3 years. 2h Glucose Tolerance\.br\Test is indicated if 1 or more risk fac-\.br\tors present. www.bcguidelines.ca/gpac/\.br\pdf/diabetes_appendix_a.pdf\.br\
ORC|RE||13-900900006-LYTE-1|||||||||90909^MDCARE^BOB
OBR|4||13-900900006-LYTE-1|LYTE^Electrolytes||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|2951-2^Sodium||139|mmol/L|134-145|N|||F|||20130911172003
OBX|2|NM|2823-3^Potassium||4.5|mmol/L|3.5-5.0|N|||F|||20130911172003
ORC|RE||13-900900006-CRE-1|||||||||90909^MDCARE^BOB
OBR|5||13-900900006-CRE-1|CRE^Creatinine/eGFR||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|14682-9^Creatinine||72|umol/L|70-120|N|||F|||20130911172003
OBX|2|NM|33914-3^Estimated GFR||98|mL/min|>=60|N|||F|||20130911172003
NTE|||For further information see\.br\http://www.bcguidelines.ca/gpac/\.br\pdf/ckd.pdf\.br\
ORC|RE||13-900900006-YGT-1|||||||||90909^MDCARE^BOB
OBR|6||13-900900006-YGT-1|YGT^Gamma GT||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|2324-2^Gamma GT||42|U/L|10-58|N|||F|||20130911172003
ORC|RE||13-900900006-ALT-1|||||||||90909^MDCARE^BOB
OBR|7||13-900900006-ALT-1|ALT^ALT||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|1742-6^ALT||61|U/L|<60|A|||F|||20130911172003
ORC|RE||13-900900006-AST-1|||||||||90909^MDCARE^BOB
OBR|8||13-900900006-AST-1|AST^AST||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM4|F|||90909^MDCARE^BOB
OBX|1|NM|1920-8^AST||42|U/L|<35|A|||F|||20130911172003
ORC|RE||13-900900006-LIP-1|||||||||90909^MDCARE^BOB
OBR|9||13-900900006-LIP-1|LIP^Lipids||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM6|F|||90909^MDCARE^BOB
NTE|||Fasting?: YES
OBX|1|NM|14647-2^Cholesterol||4.82|mmol/L|2.00-5.19|N|||F|||20130911172003
OBX|2|NM|39469-2^LDL Cholesterol||2.75|mmol/L|1.50-3.39|N|||F|||20130911172003
NTE|||The LDL-C target for moderate and high\.br\risk individuals is less than 2.0 mmol/L\.br\or a reduction of 50% or more. For low \.br\risk individuals, the LDL-C target is a \.br\reduction of 50% or more. See Can. J. \.br\Cardiol. 2009\.br\25(10):567-569.\.br\
OBX|3|NM|14646-4^HDL Cholesterol||1.31|mmol/L|>0.90|N|||F|||20130911172003
OBX|4|NM|32309-7^Chol/HDL (Risk Ratio)||3.68||<4.9|N|||F|||20130911172003
OBX|5|NM|14927-8^Triglycerides||1.67|mmol/L|0.45-2.29|N|||F|||20130911172003
ORC|RE||13-900900006-TSR-1|||||||||90909^MDCARE^BOB
OBR|10||13-900900006-TSR-1|TSR^TSH||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM11|F|||90909^MDCARE^BOB
OBX|1|NM|3016-3^TSH||3.1|mU/L|0.27-4.2|N|||F|||20130911172003
ORC|RE||13-900900006-PSE-1|||||||||90909^MDCARE^BOB
OBR|11||13-900900006-PSE-1|PSE^PSA||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM14|F|||90909^MDCARE^BOB
OBX|1|NM|2857-1^PSA||1.1|ug/L|<3.5|N|||F|||20130911172003
NTE|||Changes in serial PSA levels may be\.br\misleading unless all PSA tests are\.br\performed by the same laboratory.\.br\\.br\Additional information available at\.br\www.lifelabs.com\.br\
ORC|RE||13-900900006-OB-1|||||||||90909^MDCARE^BOB
OBR|12||13-900900006-OB-1|OB^Occult Blood Fecal||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||CHEM25|F|||90909^MDCARE^BOB
NTE|||Immuno Faecal Occult Blood\.br\Date of requisition: Unknown\.br\FIT kit provided today.
ORC|RE||13-900900006-URC-1|||||||||90909^MDCARE^BOB
OBR|13||13-900900006-URC-1|URC^Urine Culture||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||MICRO3|F|||90909^MDCARE^BOB
OBX|1|FT|X10025^Comment||Urine culture not performed as urinalysis criteria\.br\not met according to MSC protocol.\.br\||||||F|||20130911172003
ORC|RE||13-900900006-ECG-1|||||||||90909^MDCARE^BOB
OBR|14||13-900900006-ECG-1|ECG^ECG||20130911081700|20130911081700|||||||20130911081700||90909^MDCARE^BOB||||||20130911172003||REFER1|F|||90909^MDCARE^BOB
NTE|||Electrocardiogram\.br\Forwarded to the Cardiologist\.br\Interpretation will be sent directly to\.br\the ordering physician within three to\.br\five business days.
]]></Message><Message MsgID="14"><![CDATA[MSH|^~\&|PATHL7|PRH|HTTPCLIENT|vendor1|20130927130552||ORU^R01|ACC20130927130551217|P|2.3|||ER|AL
PID||9040555789|PR99970662||EXCELLERIS^KPATIENT||19700603|M|||||(604)212-1122
ORC|RE||1209:BG99925S-341892-GCM-1|||||||||90909^MDCARE^BOB
OBR|1||1209:BG99925S-341892-GCM-1|GCM^General Information|||20130912143000|||||||20130912143800||90909^MDCARE^BOB||||||20130912143800||GENERAL|F|||90909^MDCARE^BOB
NTE|||Provincial Health Care No. : 9040555789\.br\COLLECTED BY: MM\.br\PT ON OXYGEN? NO\.br\SPECIMEN TYPE: ARTERIAL
ORC|RE||1209:BG99925S-341892-BGAS-1|||||||||90909^MDCARE^BOB
OBR|2||1209:BG99925S-341892-BGAS-1|BGAS^Blood Gases|||20130912143000|||||||20130912143800||90909^MDCARE^BOB||||||20130912143800||CHEM3.5|F|||90909^MDCARE^BOB
OBX|1|FT|31208-2^Specimen Source||ARTERIAL||||||F|||20130912143800
OBX|2|FT|X10219^Mode of Oxygen||ROOM AIR||||||F|||20130912143800
OBX|3|NM|11558-4^pH||7.47||7.35-7.45|H|||F|||20130912143800
OBX|4|NM|11557-6^pCO2||34|mm Hg|35-45|L|||F|||20130912143800
OBX|5|NM|11556-8^pO2||87|mm Hg|>80||||F|||20130912143800
OBX|6|NM|1959-6^HCO3||24|mmol/L|21-28||||F|||20130912143800
OBX|7|NM|11555-0^Base Excess||1.8|mmol/L|-3 TO 3||||F|||20130912143800
OBX|8|NM|20564-1^O2 Saturation||96.7|%|94-100||||F|||20130912143800
]]></Message><Message MsgID="15"><![CDATA[MSH|^~\&|PATHL7|SG|HTTPCLIENT|vendor1|20130927130552||ORU^R01|ACC20130927130551218|P|2.3|||ER|AL
PID||1009000333|64127||EXCELLERIS^SBABY||20130909|F
ORC|RE||13QA9952-13QA9952-NEWB-1|||||||||90909^MDCARE^BOB
OBR|1||13QA9952-13QA9952-NEWB-1|NEWB^Newborn Metabolic Screen|||20130915102700|||||||20130916151500||90909^MDCARE^BOB||||||20130918133500||CHEM15.3|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|FT|X10418^Mother's Name||EXCELLERIS, KATHRYN||||||F|||20130918133500
OBX|2|FT|XXX-0140^Mother's Provinicial Health Number||9009000494||||||F|||20130918133500
OBX|3|FT|46733-2^Amino Acid Disorders||Negative Screen||||||F|||20130918133500
OBX|4|FT|46736-5^Fatty Acid Oxidation Disorders||Negative Screen||||||F|||20130918133500
OBX|5|FT|46744-9^Organic Acid Disorders||Negative Screen||||||F|||20130918133500
OBX|6|FT|46735-7^Endocrine Disorders||Negative Screen||||||F|||20130918133500
NTE|||Note: Hypothyroidism can develop at any time during infancy or childhood.
OBX|7|FT|46740-7^Hemoglobinopathies||Negative Screen||||||F|||20130918133500
OBX|8|FT|46737-3^Galactosemia||Negative Screen||||||F|||20130918133500
OBX|9|FT|46769-6^Cystic Fibrosis||Negative Screen||||||F|||20130918133500
NTE|||Note: A small number of CF patients will screen negative in the newborn period. If there is clinical suspicion of CF (poor growth, loose stools, persistent cough, or respiratory concerns) further testing is recommended.
OBX|10|TX|XXX-2609^Summary||SCREEN NEGATIVE for all disorders.\.br\\.br\||||||F|||20130918133500
OBX|11|TX|XXX-2610^Action Required||NONE.\.br\\.br\||||||F|||20130918133500
OBX|12|TX|XXX-2611^Disorders Screened||Amino Acid Disorders (PKU,MSUD,CIT,ASA,HCY,TYR)\.br\Fatty Acid Oxidative Disorders (MCAD,VLCAD,LCHAD/TFP)\.br\Organic Acid Disorders (PROP,MMA,Cbl A/B,GAI,IVA)\.br\Endocrine Disorders (CH,CAH)\.br\Hemoglobinopathies(HbS/S,HbS/variants,Hb S/beta-Thal)\.br\Galactosemia\.br\Cystic Fibrosis\.br\\.br\||||||F|||20130918133500
OBX|13|TX|X10417^Report Footer||Newborn screening is not a diagnostic test and all positive screens must be confirmed by follow-up testing.\.br\There is also a possibility of false positive and false negative results.\.br\Any infant with clinical features suggestive of the disorders listed above should be investigated regardless of the screening results.\.br\For additional information, see: www.newbornscreeningbc.ca||||||F|||20130918133500
]]></Message><Message MsgID="16"><![CDATA[MSH|^~\&|PATHL7|BCCA|HTTPCLIENT|vendor1|20130927130552||ORU^R01|ACC20130927130551219|P|2.3|||ER|AL
PID||1009423006|BCC1323959||EXCELLERIS^MPATIENT||19750607|F
ORC|RE||QA13-9920-AP9999279-BCCAPATH-1|||||||||90909^MDCARE^BOB
OBR|1||QA13-9920-AP9999279-BCCAPATH-1|BCCAPATH^BCCA Pathology Report|||20130917105000|||||||20130917110300||90909^MDCARE^BOB||||||20130918152900||CELLPATH|F|||90293^COUNTRY^SQUIRE~90909^MDCARE^BOB~22333^MEDIC^IAN~20202^PARKINSON^NED~12345^TASTING^WINE
OBX|1|FT|27898-6^Pathology Studies|1|\.br\||||||F|||20130918152900
OBX|2|FT|27898-6^Pathology Studies|2|\.br\||||||F|||20130918152900
OBX|3|FT|27898-6^Pathology Studies|3|BC Cancer Agency||||||F|||20130918152900
OBX|4|FT|27898-6^Pathology Studies|4|600 West 10th Avenue||||||F|||20130918152900
OBX|5|FT|27898-6^Pathology Studies|5|Vancouver, BC||||||F|||20130918152900
OBX|6|FT|27898-6^Pathology Studies|6|V5Z 4E6||||||F|||20130918152900
OBX|7|FT|27898-6^Pathology Studies|7|Tel Number: 604.877.6000||||||F|||20130918152900
OBX|8|FT|27898-6^Pathology Studies|8|Fax Number: 604.877.6178||||||F|||20130918152900
OBX|9|FT|27898-6^Pathology Studies|9|\.br\||||||F|||20130918152900
OBX|10|FT|27898-6^Pathology Studies|10|\.br\||||||F|||20130918152900
OBX|11|FT|27898-6^Pathology Studies|11|>>::SURGICAL FINAL REPORT||||||F|||20130918152900
OBX|12|FT|27898-6^Pathology Studies|12|\.br\||||||F|||20130918152900
OBX|13|FT|27898-6^Pathology Studies|13|\.br\||||||F|||20130918152900
OBX|14|FT|27898-6^Pathology Studies|14|SPECIMEN(S) RECEIVED>>::||||||F|||20130918152900
OBX|15|FT|27898-6^Pathology Studies|15|Breast, Right, 12:30 O'Clock, Core, Biopsy||||||F|||20130918152900
OBX|16|FT|27898-6^Pathology Studies|16|\.br\||||||F|||20130918152900
OBX|17|FT|27898-6^Pathology Studies|17|\.br\||||||F|||20130918152900
OBX|18|FT|27898-6^Pathology Studies|18|CLINICAL DATA>>::||||||F|||20130918152900
OBX|19|FT|27898-6^Pathology Studies|19|Right breast 12:30 o'clock, 4.2 CFN.||||||F|||20130918152900
OBX|20|FT|27898-6^Pathology Studies|20|\.br\||||||F|||20130918152900
OBX|21|FT|27898-6^Pathology Studies|21|Radiologic Assessment:  ?Ca.||||||F|||20130918152900
OBX|22|FT|27898-6^Pathology Studies|22|\.br\||||||F|||20130918152900
OBX|23|FT|27898-6^Pathology Studies|23|GROSS DESCRIPTION>>::||||||F|||20130918152900
OBX|24|FT|27898-6^Pathology Studies|24|Received is a container labeled with the patient' s name EXCELLERIS\S\MPATIENT, date of||||||F|||20130918152900
OBX|25|FT|27898-6^Pathology Studies|25|birth 25 MAY 1964, and specimen site RIGHT BREAST CORE BIOPSY.  It comes with 1||||||F|||20130918152900
OBX|26|FT|27898-6^Pathology Studies|26|x-ray film.  The specimen is in buffered formalin.  It consists of 9 cores and||||||F|||20130918152900
OBX|27|FT|27898-6^Pathology Studies|27|multiple fragments of tan tissue.  The cores measure 18 mm to 9 mm in length,||||||F|||20130918152900
OBX|28|FT|27898-6^Pathology Studies|28|and the fragments aggregate to 10 mm in greatest dimension.  It is submitted in||||||F|||20130918152900
OBX|29|FT|27898-6^Pathology Studies|29|toto.||||||F|||20130918152900
OBX|30|FT|27898-6^Pathology Studies|30|\.br\||||||F|||20130918152900
OBX|31|FT|27898-6^Pathology Studies|31|CASSETTE KEY:||||||F|||20130918152900
OBX|32|FT|27898-6^Pathology Studies|32|A1 to A3     - 2 cores in each.||||||F|||20130918152900
OBX|33|FT|27898-6^Pathology Studies|33|A4     - 3 cores.||||||F|||20130918152900
OBX|34|FT|27898-6^Pathology Studies|34|A5     - fragments.||||||F|||20130918152900
OBX|35|FT|27898-6^Pathology Studies|35|\.br\||||||F|||20130918152900
OBX|36|FT|27898-6^Pathology Studies|36|Removed, Date and Time:          17 September 2013 at 10:50.||||||F|||20130918152900
OBX|37|FT|27898-6^Pathology Studies|37|Placed in formalin, Date and Time:     17 September 2013 at 11:00.||||||F|||20130918152900
OBX|38|FT|27898-6^Pathology Studies|38|Received, Date and Time:          17 September 2013 at 11:03.||||||F|||20130918152900
OBX|39|FT|27898-6^Pathology Studies|39|Fixation Ended, Date and Time:     17 September 2013 at 20:00.||||||F|||20130918152900
OBX|40|FT|27898-6^Pathology Studies|40|\.br\||||||F|||20130918152900
OBX|41|FT|27898-6^Pathology Studies|41|aj/17/09/2013||||||F|||20130918152900
OBX|42|FT|27898-6^Pathology Studies|42|\.br\||||||F|||20130918152900
OBX|43|FT|27898-6^Pathology Studies|43|J.C.||||||F|||20130918152900
OBX|44|FT|27898-6^Pathology Studies|44|\.br\||||||F|||20130918152900
OBX|45|FT|27898-6^Pathology Studies|45|FINAL DIAGNOSIS>>::||||||F|||20130918152900
OBX|46|FT|27898-6^Pathology Studies|46|BREAST (RIGHT, 12:30 O'CLOCK, 4.2 CMFN), NEEDLE CORE BIOPSY (9 CORES):||||||F|||20130918152900
OBX|47|FT|27898-6^Pathology Studies|47|     - DUCTAL EPITHELIAL ATYPIA, FLAT (DIN 1A):||||||F|||20130918152900
OBX|48|FT|27898-6^Pathology Studies|48|     -- MICROCALCIFICATIONS:  PRESENT.||||||F|||20130918152900
OBX|49|FT|27898-6^Pathology Studies|49|- DUCTAL EPITHELIAL HYPERPLASIA, USUAL TYPE, WITHOUT ATYPIA (UDH).||||||F|||20130918152900
OBX|50|FT|27898-6^Pathology Studies|50|- SECRETORY CHANGE, FOCAL.||||||F|||20130918152900
OBX|51|FT|27898-6^Pathology Studies|51|- FIBROCYSTIC CHANGE:  STROMAL FIBROSIS, CYST FORMATION.||||||F|||20130918152900
OBX|52|FT|27898-6^Pathology Studies|52|\.br\||||||F|||20130918152900
OBX|53|FT|27898-6^Pathology Studies|53|\.br\||||||F|||20130918152900
OBX|54|FT|27898-6^Pathology Studies|54|\.br\||||||F|||20130918152900
OBX|55|FT|27898-6^Pathology Studies|55|\.br\||||||F|||20130918152900
OBX|56|FT|27898-6^Pathology Studies|56|\.br\||||||F|||20130918152900
OBX|57|FT|27898-6^Pathology Studies|57|ad/18/09/2013||||||F|||20130918152900
OBX|58|FT|27898-6^Pathology Studies|58|\.br\||||||F|||20130918152900
OBX|59|FT|27898-6^Pathology Studies|59|***Electronically Signed Out***||||||F|||20130918152900
OBX|60|FT|27898-6^Pathology Studies|60|T. H., MD, FRCPC            Pathologist||||||F|||20130918152900
OBX|61|FT|27898-6^Pathology Studies|61|\.br\||||||F|||20130918152900
OBX|62|FT|27898-6^Pathology Studies|62|\.br\||||||F|||20130918152900
OBX|63|FT|27898-6^Pathology Studies|63|\.br\||||||F|||20130918152900
OBX|64|FT|27898-6^Pathology Studies|64|\.br\||||||F|||20130918152900
OBX|65|FT|27898-6^Pathology Studies|65|\.br\||||||F|||20130918152900
OBX|66|FT|27898-6^Pathology Studies|66|\.br\||||||F|||20130918152900
OBX|67|FT|27898-6^Pathology Studies|67|\.br\||||||F|||20130918152900
]]></Message><Message MsgID="17"><![CDATA[MSH|^~\&|PATHL7|VIHA|HTTPCLIENT|vendor1|20130927130552||ORU^R01|ACC20130927130551220|P|2.3|||ER|AL
PID||9039039033|16413189||EXCELLERIS^IPATIENT||19611202|F|||||(250)876-7676
ORC|RE||13-999-009903-CRC-0|||||||||90909^MDCARE^BOB
OBR|1||13-999-009903-CRC-0|CRC^Creatinine Clearance 24h|RT|20130919172000|20130918061500|||||||20130919172000||90909^MDCARE^BOB||||||20130920123355||CHEM9|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|14683-7^Urine Creatinine||2.0|mmol/L|||||F|||20130920113629
OBX|2|NM|14684-5^Urine Creatinine||4.8|mmol/d|7.7-17.7|L|||F|||20130920113629
OBX|3|NM|2164-2^Creatinine Clearance 24h||0.68|mL/s|0.90-2.30|L|||F|||20130920123355
ORC|RE||13-999-009903-TVOL-0|||||||||90909^MDCARE^BOB
OBR|2||13-999-009903-TVOL-0|TVOL^Urine Volume Timed|RT|20130919172000|20130918061500|||||||20130919172000||90909^MDCARE^BOB||||||20130920113630||CHEM9|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|3167-4^Urine Volume||2.40|L|0.50-1.50|H|||F|||20130920093011
OBX|2|NM|13362-9^Collection Duration||24|h|||||F|||20130920093011
ORC|RE||13-999-009903-UPR-0|||||||||90909^MDCARE^BOB
OBR|3||13-999-009903-UPR-0|UPR^Urine Protein Timed|RT|20130919172000|20130918061500|||||||20130919172000||90909^MDCARE^BOB||||||20130920113630||CHEM9|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|2888-6^Urine Protein Random||0.37|g/L|||||F|||20130920113629
OBX|2|NM|2889-4^Urine Protein||0.89|g/d|0.00-0.15|H|||F|||20130920113629
OBX|3|NM|XXX-2000^Urine Protein/Creatinine Ratio||185|g/mol|0-23|H|||F|||20130920113629
ORC|RE||13-999-009903-UEP-0|||||||||90909^MDCARE^BOB
OBR|4||13-999-009903-UEP-0|UEP^Urine Protein Electrophoresis 24h|RT|20130923074100|20130918061500|||||||20130923074100||90909^MDCARE^BOB||||||20130925082453||CHEM9|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|XXX-2001^Concentration Factor||50||||||F|||20130925082453
OBX|2|FT|59465-5^Pathologist Review||Moderate proteinuria.  Predominantly albumin with bands corresponding to alpha-1, alpha-2 globulins and transferrin seen.\.br\Pattern is consistent with mild/moderate glomerular impairment. (eGFR= 53 mL/min)\.br\\.br\G.H., MD||||||F|||20130925082453
ORC|RE||13-999-009903-UNA24-0|||||||||90909^MDCARE^BOB
OBR|5||13-999-009903-UNA24-0|UNA24^Urine Sodium 24h|RT|20130919172000|20130918061500|||||||20130919172000||90909^MDCARE^BOB||||||20130920113630||CHEM9|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|2955-3^Urine Sodium||25|mmol/L|||||F|||20130920113629
OBX|2|NM|2956-1^Urine Sodium 24h||60|mmol/d|100-260|L|||F|||20130920113629
]]></Message><Message MsgID="18"><![CDATA[MSH|^~\&|PATHL7|CW|HTTPCLIENT|vendor1|20130927130552||ORU^R01|ACC20130927130551221|P|2.3|||ER|AL
PID||1008203001|CWH9000067||EXCELLERIS^OPATIENT||20051112|M|||||604-658-2003
ORC|RE||S13-9026-AP9000023-SPR-1|||||||||90909^MDCARE^BOB
OBR|1||S13-9026-AP9000023-SPR-1|SPR^Surgical Pathology Report|||20130924123800|||||||20130924123800||90909^MDCARE^BOB||||||20130925171700||CELLPATH|F|||90909^MDCARE^BOB
OBX|1|FT|27898-6^Pathology Studies|1|\.br\||||||F|||20130925171700
OBX|2|FT|27898-6^Pathology Studies|2|\.br\||||||F|||20130925171700
OBX|3|FT|27898-6^Pathology Studies|3|Children's and Women's Health Centre of British Columbia||||||F|||20130925171700
OBX|4|FT|27898-6^Pathology Studies|4|4500 Oak Street||||||F|||20130925171700
OBX|5|FT|27898-6^Pathology Studies|5|Vancouver, BC||||||F|||20130925171700
OBX|6|FT|27898-6^Pathology Studies|6|V6H 3N1||||||F|||20130925171700
OBX|7|FT|27898-6^Pathology Studies|7|Tel Number: 604.875.3422||||||F|||20130925171700
OBX|8|FT|27898-6^Pathology Studies|8|Fax Number: 604.875.3529||||||F|||20130925171700
OBX|9|FT|27898-6^Pathology Studies|9|\.br\||||||F|||20130925171700
OBX|10|FT|27898-6^Pathology Studies|10|\.br\||||||F|||20130925171700
OBX|11|FT|27898-6^Pathology Studies|11|>>::SURGICAL PATHOLOGY REPORT||||||F|||20130925171700
OBX|12|FT|27898-6^Pathology Studies|12|\.br\||||||F|||20130925171700
OBX|13|FT|27898-6^Pathology Studies|13|Accession # S13-9026||||||F|||20130925171700
OBX|14|FT|27898-6^Pathology Studies|14|\.br\||||||F|||20130925171700
OBX|15|FT|27898-6^Pathology Studies|15|\.br\||||||F|||20130925171700
OBX|16|FT|27898-6^Pathology Studies|16|SPECIMEN SOURCE>>::||||||F|||20130925171700
OBX|17|FT|27898-6^Pathology Studies|17|Punch biopsy, right leg||||||F|||20130925171700
OBX|18|FT|27898-6^Pathology Studies|18|\.br\||||||F|||20130925171700
OBX|19|FT|27898-6^Pathology Studies|19|FINAL DIAGNOSIS>>::||||||F|||20130925171700
OBX|20|FT|27898-6^Pathology Studies|20|SKIN, RIGHT LEG, PUNCH BIOPSY:||||||F|||20130925171700
OBX|21|FT|27898-6^Pathology Studies|21|1. CELLULITIS, WITH YEAST FORMS IDENTIFIED IN THE DERMIS BY GMS AND PAS STAINS.||||||F|||20130925171700
OBX|22|FT|27898-6^Pathology Studies|22|2. PCR TO ATTEMPT TO IDENTIFY THE SPECIES IS PENDING (TEST PERFORMED AT BCCDC).||||||F|||20130925171700
OBX|23|FT|27898-6^Pathology Studies|23|\.br\||||||F|||20130925171700
OBX|24|FT|27898-6^Pathology Studies|24|PLEASE SEE DIAGNOSIS COMMENT AND MICROSCOPIC DESCRIPTION.||||||F|||20130925171700
OBX|25|FT|27898-6^Pathology Studies|25|\.br\||||||F|||20130925171700
OBX|26|FT|27898-6^Pathology Studies|26|AL  25/09/2013||||||F|||20130925171700
OBX|27|FT|27898-6^Pathology Studies|27|\.br\||||||F|||20130925171700
OBX|28|FT|27898-6^Pathology Studies|28|COMMENT>>::||||||F|||20130925171700
OBX|29|FT|27898-6^Pathology Studies|29|Selected slides were shown to Dr. R. C., dermatopathologist (VGH), and Dr.||||||F|||20130925171700
OBX|30|FT|27898-6^Pathology Studies|30|P. T., medical microbiologist, who agree with the interpretation.||||||F|||20130925171700
OBX|31|FT|27898-6^Pathology Studies|31|Preliminary findings discussed with Dr. C.(ICU) on September 25, 2013 at||||||F|||20130925171700
OBX|32|FT|27898-6^Pathology Studies|32|1410 hours, with the infectious diseases team at 1445 hours, and with Dr. H.||||||F|||20130925171700
OBX|33|FT|27898-6^Pathology Studies|33|(Dermatology) at 1600 hours.||||||F|||20130925171700
OBX|34|FT|27898-6^Pathology Studies|34|\.br\||||||F|||20130925171700
OBX|35|FT|27898-6^Pathology Studies|35|Fungal PCR at BCCDC will be requested in an attempt to speciate the yeast.||||||F|||20130925171700
OBX|36|FT|27898-6^Pathology Studies|36|Results will be amended to this report once available.||||||F|||20130925171700
OBX|37|FT|27898-6^Pathology Studies|37|\.br\||||||F|||20130925171700
OBX|38|FT|27898-6^Pathology Studies|38|AL  25/09/2013||||||F|||20130925171700
OBX|39|FT|27898-6^Pathology Studies|39|\.br\||||||F|||20130925171700
OBX|40|FT|27898-6^Pathology Studies|40|\.br\||||||F|||20130925171700
OBX|41|FT|27898-6^Pathology Studies|41|\.br\||||||F|||20130925171700
OBX|42|FT|27898-6^Pathology Studies|42|\.br\||||||F|||20130925171700
OBX|43|FT|27898-6^Pathology Studies|43|al/25/09/2013||||||F|||20130925171700
OBX|44|FT|27898-6^Pathology Studies|44|***Electronically Signed Out***||||||F|||20130925171700
OBX|45|FT|27898-6^Pathology Studies|45|A.L., PATHOLOGIST||||||F|||20130925171700
OBX|46|FT|27898-6^Pathology Studies|46|\.br\||||||F|||20130925171700
OBX|47|FT|27898-6^Pathology Studies|47|CLINICAL HISTORY>>::||||||F|||20130925171700
OBX|48|FT|27898-6^Pathology Studies|48|ALL (B-cell) induction D25, complicated by sepsis.||||||F|||20130925171700
OBX|49|FT|27898-6^Pathology Studies|49|24 hr history of palpable purpuric lesions with central necrosis on both lower||||||F|||20130925171700
OBX|50|FT|27898-6^Pathology Studies|50|legs and disseminated petechiae.  Vasculitic/thrombotic.||||||F|||20130925171700
OBX|51|FT|27898-6^Pathology Studies|51|Imp:  thrombotic septic embolis - ? fungal (?aspergillus/candida).||||||F|||20130925171700
OBX|52|FT|27898-6^Pathology Studies|52|        vasculitis.  differential diagnosis  ecthyma gangrenosum.||||||F|||20130925171700
OBX|53|FT|27898-6^Pathology Studies|53|\.br\||||||F|||20130925171700
OBX|54|FT|27898-6^Pathology Studies|54|\.br\||||||F|||20130925171700
OBX|55|FT|27898-6^Pathology Studies|55|\.br\||||||F|||20130925171700
OBX|56|FT|27898-6^Pathology Studies|56|\.br\||||||F|||20130925171700
OBX|57|FT|27898-6^Pathology Studies|57|GROSS DESCRIPTION>>::||||||F|||20130925171700
OBX|58|FT|27898-6^Pathology Studies|58|Received in a single container of formalin labeled with the patient's name, unit||||||F|||20130925171700
OBX|59|FT|27898-6^Pathology Studies|59|number and "SKIN BIOPSY R LEG" is a 0.4 x 0.3 x 0.7 (depth) segment of skin with||||||F|||20130925171700
OBX|60|FT|27898-6^Pathology Studies|60|a dusky grey-tan smooth surface.  The deep margins are painted black and the||||||F|||20130925171700
OBX|61|FT|27898-6^Pathology Studies|61|specimen is submitted in toto in cassette A1.||||||F|||20130925171700
OBX|62|FT|27898-6^Pathology Studies|62|\.br\||||||F|||20130925171700
OBX|63|FT|27898-6^Pathology Studies|63|Dictated By:  AA 24/09/2013||||||F|||20130925171700
OBX|64|FT|27898-6^Pathology Studies|64|\.br\||||||F|||20130925171700
OBX|65|FT|27898-6^Pathology Studies|65|\.br\||||||F|||20130925171700
OBX|66|FT|27898-6^Pathology Studies|66|\.br\||||||F|||20130925171700
OBX|67|FT|27898-6^Pathology Studies|67|MICROSCOPIC DESCRIPTION>>::||||||F|||20130925171700
OBX|68|FT|27898-6^Pathology Studies|68|Sections show a punch biopsy of skin excised to the subcutis. The epidermis is||||||F|||20130925171700
OBX|69|FT|27898-6^Pathology Studies|69|intact and viable. There is superficial perivascular dermal lymphocytic||||||F|||20130925171700
OBX|70|FT|27898-6^Pathology Studies|70|inflammation. There is patchy hemorrhage in the superficial and deep dermal||||||F|||20130925171700
OBX|71|FT|27898-6^Pathology Studies|71|connective tissue. The mid-to-deep dermis shows neutrophilic microabscesses and||||||F|||20130925171700
OBX|72|FT|27898-6^Pathology Studies|72|lymphohistiocytic aggregates clustered around small vessels. The vessels are||||||F|||20130925171700
OBX|73|FT|27898-6^Pathology Studies|73|prominent and lined by plump endothelial cells, but no microthrombi or||||||F|||20130925171700
OBX|74|FT|27898-6^Pathology Studies|74|vasculitis is seen.||||||F|||20130925171700
OBX|75|FT|27898-6^Pathology Studies|75|\.br\||||||F|||20130925171700
OBX|76|FT|27898-6^Pathology Studies|76|Within the mid-dermal inflammatory infiltrate, PAS and GMS special stains||||||F|||20130925171700
OBX|77|FT|27898-6^Pathology Studies|77|highlight round to ovoid organisms that show occasional budding, morphologically||||||F|||20130925171700
OBX|78|FT|27898-6^Pathology Studies|78|consistent with yeast. No hyphae or pseudohyphae are seen. It is not possible to||||||F|||20130925171700
OBX|79|FT|27898-6^Pathology Studies|79|speciate this organism on morphologic grounds alone.||||||F|||20130925171700
OBX|80|FT|27898-6^Pathology Studies|80|\.br\||||||F|||20130925171700
OBX|81|FT|27898-6^Pathology Studies|81|\.br\||||||F|||20130925171700
OBX|82|FT|27898-6^Pathology Studies|82|\.br\||||||F|||20130925171700
OBX|83|FT|27898-6^Pathology Studies|83|\.br\||||||F|||20130925171700
]]></Message></HL7Messages>
